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ABSTRACT

In the last two decades, primary cilia have become recognized as tiny sensory
organelles with considerable physiological function including regulation of cell division
and modulation of transduction pathways. Scientists build on former discoveries,
identifying new connections and accentuating the value of primary cilia in disease and
intercellular signaling. Astrocytes, the most numerous cell type within the brain, act in
support of neurons and maintain neurological health by providing neurotrophic factors
and removing synaptic debris. These cells are particularly significant in reparations
following neural injury and diseases, altering shape and function to protect healthy
tissue. Astrocytes display primary cilia, yet little is understood about the function of this
organelle within these cells.
My dissertation research sought to determine the morphological changes of
astrocytic primary cilia under neuropathological conditions, such as brain injury and
epilepsy, and explore electroencephalogram activity under anesthesia in a mouse
model of Alzheimer’s disease (AD). This research comprised of three major projects: (1)
identifying morphological and condition-based differences between neuronal and
astrocytic primary cilia, (2) evaluating the implications of Arl13B during cortical injury,
and (3) quantifying EEG waveform pattern in an AD mouse model for distinctions
indicative of the presence of the disease prior to the phenotypic onset.
Immunohistochemistry was used to explore morphological differences and
alterations in primary cilia associated with cell-type and the development of astrocytic
reactivity. Cortical injury procedures were used to form a localized astrocytic response
in Arl13B loss-of-function and gain-of-function strains, as well as an IFT88 knockout
xii

strain

to

compare

the

role

of

Arl13B

in

glial

scarring.

Electroencephalogram/electromyogram (EEG/EMG) recordings were furthermore used
to substantiate seizure activity in a strain of mice prone to epileptic behavior.
Finally, the APP23 mouse, a murine model of AD, was exposed to isoflurane
anesthesia while EEG waveform was recorded. These recordings were filtered and
processed via Brainstorm, a MATLAB graphical interface, and analyzed for Power
Spectral Density, Burst Suppression Density, and Phase Amplitude Coupling.
Results of morphological changes in cilia were consistent with the hypothesis
that similarly to neuronal primary cilia, astrocytic cilia are implicated under reactive
conditions assessed by morphological changes. Immunohistochemical analysis also
revealed regional and strain differences of primary cilia. However, comparison of Lossof-Function and Gain-of-Function studies did not collectively support the hypothesis that
the ciliary protein Arl13B is a functionally relevant component of GFAP-based
neurological repair one week following injury, although injured tissue did consistently
show heightened Arl13B close to cortical lesion.
Finally, EEG waveform analysis of a mouse model of AD during exposure to
anesthesia revealed 3-4-month-old mice show a statistically significant difference in
levels of Burst Suppression Density during anesthesia and Power Spectral Densities of
Delta, Theta, and Alpha. These results support the potential foundation of waveform
analysis during anesthesia as a prudent diagnostic tool to allow for early diagnosis of
the disease.

xiii

This research elucidates (1) the role of astrocytic primary cilia in the pathogenic
brain, (2) relevance of Arl13B in brain injury, and (3) provides a possible basis for
quantifiable hallmarks of AD in EEG waveform under isoflurane-induced anesthesia.

xiv

Chapter 1

INTRODUCTION & BACKGROUND

Within the brain, astrocytes function in the regulation of neuronal functioning by
providing neurons with essential substrates, modeling synapses, and demarcating
healthy and necrotic tissue [1]. They are primary responders to pathogenic conditions,
including brain injury, epilepsy, multiple sclerosis, and numerous other diseases [1].
Under these conditions, astrocytes change morphology, alter function, and sometimes
proliferate in the development of “reactivity” [2-4]. The type and extent of pathology
affect the degree of response of astrocytes, which additionally varies between
organisms [5].
Astrocytes display a singular primary cilium, a minute structure that has signaling
and sensory capacities [6-8]. Primary cilia are known to be essential to the entry of
mitosis in most vertebrate cells [9]. Thus, astrocyte reactivity marked by signal-induced
morphological alterations requires functional primary cilia to ensure effective
proliferation of new cells. Furthermore, Arl13B, a ciliary protein highly expressed in
mature astrocytic cilia, is reportedly unique in its GTPase activity, but remains unclear in
its range of functionality. It is known to regulate the Sonic Hedgehog pathway [10], a
pathway upregulated in brain injury [11], and has been reported to display increased
intensity proximal to cortical injury [6], but its role in neurological homeostasis is unclear.
AD is the most common form of dementia in the United States, accounting for
over half of reported cases [12]. Although its etiology is not fully understood, many
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advancements in understanding the development of AD have occurred through current
research. There is no cure of AD to fully reverse the clinical symptoms, and early
intervention allows for the best management of its physiological effects and associated
changes in behavior. Yet, there is limited diagnostic capacity while the patient
suspected of AD is living [13]. This presents the clinical need to identify new methods to
evaluate the incidence of AD, preferably in a non-invasive and cost-effective technique.

i.

Primary Cilia

Primary cilia are tiny, microtubule-based structures that protrude from the surface
of most vertebrate cells. They were first named by Sergei Sorokin in 1968, after
determination of the foundational dynamics of ciliogenesis in fetal lung cells [14].
Decades of research have yielded findings underscoring ciliary importance in cellular
function and physiological homeostasis including initiation of mitosis [9] and regulation
of brain development [15]. Furthermore, primary cilia are involved in modulation of the
sonic hedgehog pathway, a pathway that regulates development [10, 16], as well as
cellular mechanoreception [7, 9, 17, 18]. Additionally, scientific findings have
demonstrated the importance of primary cilia in many diseases, termed “ciliopathies”,
wherein ciliary dysfunction can elicit physiological defects [19].
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Primary Cilium

Motile Cilium

IFT-B Particle

IFT-A Particle

Ciliary Membrane

IFT-B Particle

IFT-A Particle

Primary Cilium

Basal
Body

Figure 1: Primary Cilia Axoneme Structure and Intraflagellar Transport. The primary cilia axoneme is
composed of nine outer doublets without the inner doublet found within motile cilia. IFT-A particles traffic
elements in a retrograde direction towards the basal body, while IFT-B particles carry cargo towards the
ciliary tip in an anterograde direction.

Primary cilia differ from motile cilia in structure and function. The cytoskeletal
organization that forms the internal design of primary and motile cilia is called the
“axoneme” [20, 21]. This microtubule-based axoneme is comprised of nine outer
doublets and either two or zero inner doublets [20, 21] (Figure 1). The presence of two
inner doublets supports the mobile functionality of motile cilia, while the absence of an
inner doublet prevents movement of the primary cilium [20].
Within the axoneme, intraflagellar transport (IFT) is vital to the extension of
primary cilia that must occur during ciliogenesis, as well as the trafficking of proteins
through the cilium [20, 22]. As primary cilia lack the machinery necessary for protein
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synthesis, proteins must first be synthesized in the Golgi apparatus and then
transported to the base of the cilium [20]. Two complexes comprised of small particles
and motor proteins, IFT-A and IFT-B, propel cargo in retrograde and anterograde
directions, respectively [20, 23]. The transition zone, a specialized region located at the
base of the primary cilium, controls the translocation of proteins into and out of the cilia
[20, 24]. Figure 1 shows a detailed representation of the structure and transport
proteins of primary cilia.
Dismantling of primary cilia is reported to function in the initiation of mitosis in
ciliated cells [9]. They arise from the mother centriole, termed the “basal body”, and
maintain their form as a cell surface projection during interphase [9, 17]. Prior to the
entrance of mitosis, the primary cilium must first undergo translocation of ciliary
proteins, thereby causing structure decapitation, and then retraction into the cell [9, 17].
This resorption allows the mother and daughter centrioles to duplicate and migrate to
different poles of the cell to produce spindle fibers needed during metaphase and
anaphase [9, 17]. Only by this resorption and translocation can effective mitosis occur
within a ciliated cell.
Consequently, defects in the resorption or projection of primary cilia can result in
abrogated or heightened cell proliferation, thus impacting the development of certain
forms of cancer. Some of these include: medulloblastomas [25, 26], glioblastomas [2729], and pancreatic cancer [30, 31]. Additionally, the involvement of primary cilia in
modulation of certain cell signaling pathways, including Sonic Hedgehog [10, 32], Wnt
[32], and ERK/MAPK [32] is also known to contribute to the development of certain
types of cancer by means of altered ciliary signaling pathways.
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Primary cilia are recognized to play an essential role in a range of diseases.
Pathologies that are directly attributed to the malfunction of primary cilia belong to a
spectrum called “ciliopathies” [19], which include diseases such as: polycystic kidney
disease resulting from impaired mechanoreception of urine in the kidney [33, 34];
Joubert Syndrome, a disease resulting from an impaired ciliary protein and defective
cilia [35]; Bardet-Beidl Syndrome, a condition caused by impaired basal bodies and
correlated ciliary defects (BBS) [35]; amongst numerous others. These conditions are
respectively characterized by cysts within the kidneys [33], polydactyly and cognitive
delay [36, 37], and obesity along with cognitive delay and renal malformations [38].
Primary cilia also function in detection of extracellular signals. They are thought
to act as mechanoreceptors that instigate Ca2+ signaling [39] and act to sense fluid flow
within the kidney [34]. Neuronal primary cilia are known to maintain regulatory enzymes,
such as Adenylyl Cyclase III, Melanin-concentrating hormone receptor type 1,
Somatostatin receptor type 3, and serotonin receptor type 6, signifying further
involvement in sensory input [40, 41]. Additionally, BBS, a ciliopathy resulting from
malfunctioning basal bodies and primary cilia, is characterized by anosmia and retinal
degeneration, likewise supporting primary cilia as having sensory roles [18, 42, 43].
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Figure 2: Neuronal and Astrocytic Primary Cilia in the Mature Brain. Figure sourced from Sterpka
and Chen, 2018 [7]. Mature neurons and astrocytes exhibit primary cilia, arising from the mother
centriole. Neuronal cilia are known to exhibit membrane proteins, including 5-HT6, AC3, SSTR3, and
MCHR1 [7]. Astrocytic cilia are known to exhibits Arl13B in their membrane and shuttle Sonic Hedgehog
components Smoothened and Patched1 pendant on ligand binding [7].

Within the mature brain, astrocytes and neurons are known to maintain primary
cilia (Figure 2) [6, 7]. Studies have shown that cells display variance in existence of
these organelles, and that function and morphology are not conserved [6, 7, 16, 44-47].
Cellular function likely results in the diversity of ciliary morphology and functionality.
Neurons are reported to maintain longer cilia than those of astrocytes [6, 7, 48]. The
non-mitotic nature of neurons compared to the proliferative capacity of astrocytes may
explicate why the cilia show a marked difference in length. Table 2 outlines the
differences between neuronal and astrocytic primary cilia. Immature oligodendrocyte
precursors are reported to exhibit primary cilia, although in maturity no ciliary
appendage can be distinguished [49]. It is possible that the lack of distinguishable
primary cilia in oligodendrocytes may be due to ineffective antibodies or a differential
functioning at maturity. Furthermore, microglia, similar to other immune cells within the
body, do not exhibit cilia, regardless of their continued modulation of Shh components
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[7, 48]. This variation suggests ciliary diversity may be due to the functional differences
of the cell type.
Due to their minute size, primary cilia present investigative challenges. There are
limited antibodies known to effectively stain ciliary proteins, and there is no ubiquitous
marker that can identify all primary cilia. This is especially true with in vivo research,
which poses more opportunity for background with non-specific binding. Ciliary
knockout mice are one of the more commonly used experimental tools for loss-offunction study. IFT88 mice crossed with a tamoxifen inducible Cre strain synthesize a
hybrid strain that can conditionally knockout ubiquitous or cell-specific primary cilia [50,
51]. Furthermore, lines of transgenic mice have been procured that contain fluorescent
proteins linked to ciliary protein, such as the Arl13B-mCherry;Centrin2-GFP mouse,
which allow for more efficient visualization of primary cilia [52].

Table 2. Neuronal and Astrocytic Primary Cilia in the Mature Brain
Features

Neurons

Astrocytes

Origination

Excitability

Ectoderm [53]
Neuroepithelial Cells and Radial Glial Cells
[54]
Excitable

Ectoderm [53]
Neuroepithelial Cells and Radial Glial
Cells[54]
Non-excitable

Differentiation

Terminally differentiated [55]

Proliferative Capacity

Lose mitotic ability in maturation [55]

Cilia Markers

AC3, SSTR3, 5-HT6 & MCHR1 [48]

Regional differentiation & become reactive
in response to insults
Maintain proliferative capacity throughout
life [4]
ARL13B [48]

AC3

Highly expressed in neuronal primary cilia [8]

few in astrocyte cilia in adult brain [8]

ARL13B

not well expressed in primary cilia of mature
neurons [8]

Highly expressed in astrocytic primary
cilia in the mature brain [8]

Cilia Length
(Hippocampus)

5.0–5.9 μm (AC3-positive) [48]

2.8–3.2 μm (ARL13B-positive) [48]

Shh signaling Components

Expression in primary cilia of mature neurons
not shown

Structural Dynamics

Relatively stable

Smoothened and Patched1 detected in
primary cilia of astrocytes in the postnatal
brain [25]
Subject to dynamic change during
astrocyte proliferation

Ciliogenesis

De novo ciliogenesis not reported

Maintains ciliogenesis [28, 56]

Nanoscale Structure#

Without ciliary pocket

Have ciliary pocket
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Ciliary Disease Implications

Obesity, cognitive impairment & mental
disorders [57]

Astrocytoma/glioblastoma [28, 56]

Epileptic Insults*

Neuronal primary cilia in CA1 and CA3
become shorter

ARL13B-positive astrocyte cilia become
shorter

Brain Injury Insults*

Neuronal primary cilia become shorter near
injured tissue

Arl13B-positive cilia undetectable, Arl13B
protein expression increases and translocates to the cell body

This table is modified from Sterpka and Chen 2018.
* Data from this dissertation research; # Presented by Ott CM from Janelia Research Campus.

Table 2: Comparison of Neuronal and Astrocytic Primary Cilia in the Mature Brain. Table modified
from [7, 58]. Within the mature brain, astrocytes and neurons display marked morphological and
functional differences. Their primary cilia also show differences in structure, labeling antibodies, and
pathogenic response.

ii.

Astrocytes

Astrocytes are the most prevalent cell type within the brain [4, 59, 60]. They are
markedly diverse in form and function and are essential to the survival and health of
neurons [61]. Astrocytes develop from the same progenitors as neurons [61], although
during development, astrocytes localize to the brain only after primary neurogenesis
and neural migration [62]. Relatedly, synapses only appear following the production of
astrocytes [61], and termination of astrocytes results in the inability of neuronal survival
[61].
Astrocytes participate in a wide range of functions, including the maintenance of
synapses and structure of the tripartite synapse [61-63], provision of neurotropic factors
such as lactate to neurons [64], and recycling excess neurotransmitters [65].
Importantly, astrocytes protect healthy tissue against neurological insults by altering
phenotype to become “reactive” and encompassing potentially harmful debris from
viable tissue [1, 4, 66-68].
Due to the high level of diversity in astrocytes, there is not a ubiquitous marker. It
is possible that the absence of developmental finality in astrocytes restricts the
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identification of a singular effective identifier, but presently glial fibrillary acidic protein
(GFAP) is accepted in the scientific community as the most appropriate protein which
labels the majority of astroglia and reflects the development of reactivity by heightened
expression [43]. It is an intermediate filament protein expressed in most astrocytes [68].
There are 10 known isoforms of GFAP, and their specific functions remain unclear,
apart from GFAPδ [69]. GFAPδ is reported to adjust the elements of astrocytic
intermediate filaments and be heightened in astrocytic reactivity [69].
S100B is a calcium-binding protein involved in synaptic plasticity [70]. It is
another known marker of astrocytes, but is also displayed in other cell-types, thereby
limiting its capacity to specifically mark astrocytes in immunohistological analysis [71].
Assessment of cell-type specificity of S100B revealed its expression in a high
percentage of oligodendrocytes, especially in the white matter of the brain [72].
Additionally, it was shown to be expressed in ependymal cells, lymphocytes, vascular
endothelial cells, amongst other cells in the brain [72], thus supporting the selection of
GFAP as the most effective astrocytic marker in the following studies.
Fundamentally, astrocytes have been grouped into two categories of
morphology: protoplasmic and fibrous [73]. Protoplasmic astrocytes display long
branches terminating with fine processes and are found in the grey matter of the brain
[73, 74]. Fibrous astrocytes, which display a bushier morphology with a larger number of
fine processes, primarily localize in the white matter of the brain [73, 74]. There have
been reports that protoplasmic astrocytes express S100B more heavily, while fibrous
astrocytes are reported to ordinarily express GFAP, but GFAP is recognized as the
most applicable marker for general astrocytic identification [68, 73, 74]. Although both
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types of astrocytes are reported to contact blood vessels [4], they are known to have
diversity in their functionality. Protoplasmic astrocytes are reported to play a role in
synaptic maintenance and formation of the blood brain barrier [73, 74]. Less is known
about the functional breadth of fibrous astrocytes, although it has been suggested that
they function in myelination via contact with Nodes of Ranvier [4, 73].
Astrocytes have proven to be vital to synapsing between neurons. They are
known to regulate the formation and stability of synapses [75]. Remarkably, synapses
only appear after astrocytes have differentiated [61]. By the 3rd postnatal week in mice,
astrocytes are morphologically distinguished to their locale and connect with neurons
[61]. Astrocytes release factors that alter both pre- and post-synapses, thereby inhibiting
or stimulating synaptic formation [61]. In vitro studies have shown that neurons will die
without the presence of astrocytes and also fail to synapse with one another, thereby
making them essential to neurological functioning [61].

iii.

Reactive Gliosis

Astrocytes are major proponents in maintenance of neurological homeostasis
[61, 63]. Under pathogenic conditions, in which neurological balance is disturbed such
as brain injury or epilepsy, astrocytes can become “reactive” [2, 59, 76]. Reactive
astrocytes are altered to one of two types: (1) protective of the survival of remaining
viable neurons or (2) debilitating to damaged cells [1]. Under these conditions,
astrocytes change morphology, hypertrophy, and heighten GFAP expression [1, 43, 60].
These changes are often accompanied by proliferation to support glial scarring and can
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be easily identified by additional processes and increased protein expression [77]. As a
result of this altered phenotype, tissue within the brain can be demarcated for death or
survival [1, 4]. Regardless of the functional diversity of astrocytes, all types maintain this
ability to become reactive in response to neurological disease [4].
Traumatic brain injury can elicit a range of responses based on the severity of
the event and the health profile of the afflicted individual. The injury can produce either
focal or diffuse tissue damage, which often hybridize [68]. These types of injuries can
trigger astrocytes to become reactive and proliferate to form a glial scar, although the
degree of response is region and severity dependent [4, 68, 78]. The glial scar is a
combination of reactive astrocytes, extracellular matrix proteins, and activated microglia
formed around the lesion area [79]. This assortment of protective materials appears as
a dense region of interwoven tissue. The alterations that ensue in astrocytes after the
initiation of reactivity support the protection of viable neurons from excitotoxic
substances and also support repair of the blood brain barrier [1].
The occurrence of seizures can correspond with traumatic brain injury or occur
independently, often accompanying another form of neurological condition, such as
epilepsy [68]. Epilepsy, characterized by the abnormal firing of neurons and convulsive
behaviors, is one of the most common neurological disorders [76]. Seizure activity is
accompanied by the development of astrocyte reactivity [3]. Questions regarding the
role of astrocytes in seizure activity remain, with special interest in whether the
alterations from reactivity propagate or oppose epileptic activity. Reactive astrocytes
show variation in glutamate receptors and responsiveness, possibly perpetuating
seizure activity, while also releasing factors that can promote tissue health [76, 80]. An
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understanding of astrocytic function in seizures is unclear and somewhat debated, but it
is recognized and accepted that reactive astrocytes undisputedly exist in a brain
displaying seizure activity.

iv.

ADP-ribosylation factor-like 13B (Arl13B)

Arl13B is a small GTPase belonging to the ARF family, a subset of the Ras super
family of GTPases [81-85]. It is a ciliary membrane protein, commonly used in
immunostaining of immotile primary cilia [8, 48]. It has been reported to have an
assortment of roles in the regulation of cellular function, including ciliary trafficking [86]
and migratory prompting [87, 88]. Reported to have functional diversity around the
ciliary domain, Arl13B has profound implications in physiology, morphology, and
function. Defects in this protein can elicit abnormal structure, altered capabilities, and
morbidity. The full range of functioning of Arl13B is unclear.
The Ras family of GTPases is a large group of G-proteins, divided into multiple
families [82-85, 89, 90] (Figure 3). These include Ras, Rho, Ran, Rab, Rheb, and Arf
families [83]. Grouped together due to homologous structure [82, 83], they all function in
cellular homeostasis and are divided by commonality in role [82, 83]. These include
activities in protein trafficking, cytoskeletal remodeling, and proliferation, among other
functions [82, 83]. Identified as “molecular switches [82, 83],” GTPases are activated by
Guanine-Exchange-Factors (GEFs) and deactivated by GTPase- Activating-Proteins
(GAPs), which mediate function based on effector binding [10, 68, 83-85, 89-91].
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Figure 3: Ras Super Family of GTPases. Figure sourced from Liu et al, 2018 [92]. The Ras Super
Family of GTPases is divided into multiple families of structurally and/or functionally similar proteins. ADPribosylation factors (ARFs) are a subgroup of GTP-binding proteins which maintain similar function in
membrane cargo trafficking [84]. ADP-ribosylation-factor-like proteins (Arls) are structurally similar to
ARFs, although their functionality ranges [90].

The Adenosine-diphosphate-Ribosylation Factor or “Arf” family is reported to
participate in cellular proliferation [93], selection and trafficking of cargo [83, 84, 93, 94],
and employment of enzymes [84, 94]. Arf-Like-Proteins, or Arls, are classified owing to
their structural similarity to Arfs, although they lack consistency in their functional range
[90]. Particularly unique to this group is Arl13B, which maintains a larger structure than
other Arls [82] and a distinctive range in functioning [82, 83, 95]. It is structurally unlike
other Arls due to a unique coil in its c-terminal [96] and a proline rich region in the gdomain [96]. Its full range of functioning is still unclear, but the structural variation
suggests the possibility of distinctiveness in function of Arl13B.
The ortholog Arl13 is understood by the scientific community to be lost early
during evolution in unciliated cells [97]. It is reported to only exist within ciliated cells
[95], although it is reported to function outside of the primary cilium [98, 99]. There are
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two known paralogs, Arl13A and Arl13B [100]. Arl13A is effectively underdetermined in
function, although it has been reported to be expressed in craniofacial structures during
early development of the zebrafish [100]. During early zebrafish development, Arl13A is
reported to be expressed alongside Arl13B in mitotic and ciliated cells and binds tubulin
accordingly [100]. Located on chromosome 3, specifically at 3q11.1-q11.2 [101], Arl13B
is well-studied as an atypical GTPase [102], although its full range of functioning is
unclear.
The implication of Arl13B is well established in Joubert Syndrome (JS). JS is
identified as a “ciliopathy” or disease resulting from abnormalities in ciliary function [7,
103]. 3 missense mutations in Arl13B are known to result in this autosomal recessive
disease [37] [102]. JS is characterized by a range of morphological and cognitive
abnormalities [37, 103, 104]. These include anatomical defects of the cerebellum and
brain stem known as the “molar tooth sign” [101], These neurological defects are
accompanied by cognitive delays and developmental impedances [101]. Additionally,
those afflicted with JS display renal problems such as cystic kidneys, liver abnormalities
such as hepatic fibrosis, and visual disturbances such as oculomotor apraxia [36, 37,
101, 103-105]. JS is also often accompanied by polydactyly, a morphological condition
yielding 6 digits that is shared with several other ciliopathies [101, 106].
Arl13B has been distinguished as a primary cilia marker in mature astrocytes [68, 48]. Within the adult brain, Arl13B lacks cohesive expression in other primary cilia
and is consequently the most suitable marker for labeling mature astrocytic primary
cilia. This protein can also be weakly expressed in immature neuronal cilia, but this
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expression is variable and becomes weak during cellular maturation [8]. Thus, Arl13B
can be effectively used as an astrocytic primary cilia marker [6, 7].

Figure 4: Arl13B is the GEF of Arl3. Figure sourced from Gotthardt et al., 2015 [96]. Although GTPases
are rarely activators or deactivators of other GTPases, Arl13B has been reported to have guaninenucleotide-exchange factor (GEF) activity for ARL3, and thus stimulates its ability to carry ciliary cargo
[96].

Although GTPases rarely act as GEFs, Arl13B is reported to maintain GEF
activity of another ciliary protein, Arl3 [82, 96, 102]. It is well established that Arl13b is
required to activate Arl3 (Figure 4) and induce its functioning. Arl3 is reported to assist
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with the translocation of ciliary cargo, such as phosphatidylinositol 4,5-bisphosphate 5phosphatase (Inpp5e) [82, 104, 107]. Conversely, it has been reported that Arl13B, not
Arl3, modulates the translocation of Inpp5e [82, 108]. Regardless of the conflict in
conclusions, it can be surmised that Arl13B regulates Inpp5e cargo in the primary
cilium, either directly or indirectly. As translocation of Inpp5e is integral to resorption of
primary cilia required for mitosis or ciliated cells [9], Arl13B can thus be concluded as an
essential component of cellular proliferation.
The role of Arl13B in Sonic hedgehog (Shh) is well established. Shh is a
signaling pathway necessary for cellular proliferation, survival, and embryonic patterning
[10, 66, 109]. It is well studied and now established to be propagated by Arl13B [97].
Shh pathway requires a number of components which are known to be transduced by
the primary cilium [97]. Ablation of Arl13B has been reported to weaken and reduce Shh
activity [10]. Interestingly, the function of Arl13B with respect to control of Shh signaling
was uncoupled from the primary cilium in a study by Gigante et al. [97]. In this
investigation, researchers observed the effects of a mutant form of Arl13B that was
expressed outside of the primary cilia and determined that although it elicited structural
and protein defects in the cilium itself, its presence in the cell was sufficient to regulate
Shh activity [97]. It has been reported that GPR161 (inhibitor of Shh signaling) cannot
exit the cilium in Arl13B mutants, thereby preventing activation of Shh pathway [110].
The protein Arl13B participates in the regulation of different cells within the brain,
as well as cellular migration. In 2012, Barral et al. identified a previously unknown
interaction between Arl13B and cytoskeletal actin [86], suggesting a role in cytoskeletal
remodeling and cellular movement. In vivo and in vitro studies completed by Casalou et
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al. in 2019 demonstrate that Arl13B acts to control breast cancer cell migration via
regulation of focal adhesion size and ß3-Integrin levels [87], likely a result of Arl13B’s
role in cytoskeleton alterations.
Arl13B was reported to regulate the ability of radial glia to control the proliferation
and migration of cells in the cerebral cortex [111]. Embryonic division of radial glial
creates a neurological framework which directs the orientation and generation of
neurons [111]. Higginbotham et al. revealed that time specific deletion of Arl13B
resulted in abnormal cortical development [111], thus solidifying the crucial role that
Arl13B has in neurophysiological development. Furthermore, by rendering Arl13B
inactive, Ferent et al. demonstrated that Arl13B is essential to the appropriate
commissure axon management [98]. In this study, Arl13B was targeted to manipulate
Shh, thereby affecting neuronal development [98].
Due to its implicit role in Shh activity, Arl13B has been investigated as a
therapeutic tool. In 2018, Bay et al. targeted Arl13B as a potential treatment for Shhdependent medulloblastomas (MB) [10]. To weaken and abrogate Shh function, Bay et
al. selectively deleted Arl13B. In this study, researchers effectively deleted Arl13B in MB
cell lines, as well as in an inducible Cre line of mice carrying the MB phenotype. This
effectively reduced Shh signaling and MB growths in vitro and in vivo conditions. This
study provides a foundation of Arl13B manipulation as a potential treatment of
pathologies resulting from abnormal Shh activity but did elicit a range of abnormal
anatomical and physiological problems.
Furthermore, immunohistological investigations of Arl13B-positive primary cilia
surrounding cortical injury found a dramatic reduction of ciliary presence near the lesion
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site, as well as an increased expression of Arl13B [6]. Cells proximal to the cortical
injury displayed heightened Arl13B in their soma and processes [6]. Investigation of
Arl13B-mCherry; Centrin2-GFP mice, which carry fluorescent proteins fused to Arl13B
and do not require use of an Arl13B primary antibody, displayed the same increase of
protein intensity near the injury site [6]. Although the full function of Arl13B is not yet
understood in the conditions of brain, the consistent results of increased Arl13B suggest
a previously unknown role in certain types of neurological damage.
Ablation of Arl13B is known to be embryonic lethal [112, 113]. Its deletion can
result in anatomical abnormalities [97]. In vivo ablation of Arl13B has resulted in the
presence of kidney cysts [10]. Arl13b deletion affects Shh signaling, a pathway
necessary for morphological patterning. Due to its regulation of Shh signaling, research
investigated the knockout of Arl13B to treat Shh-based cancers, such as
medulloblastomas [10].
Although the entirety of the range of functioning of Arl13B is still unclear,
scientific research has demonstrated its value in a variety of processes. It has been
proven to be integral to primary cilia by means of regulation of intraflagellar trafficking
and ciliogenesis. Relatedly, its function in vesicular transport, although not fully
understood, is undebatable. Its modulation of the Shh pathway is well recognized, and
now accepted to extend past ciliary control. It atypically maintains GEF activity of
another GTPase and modulates the migration of certain cells. Its activities pertaining to
cytoskeletal remodeling and brain injury reparations are still unclear, but Arl13B’s
implication in disease and morphological disturbances is distinct. Although categorized
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with other small GTPases, Arl13B stands out with functional diversity and unique
behavior.

v.

Adenylyl Cyclase 3 (AC3)

Adenylyl Cyclases (ACs) are a class of regulatory enzymes known to synthesize
the second messenger cyclic adenosine monophosphate (cAMP) from adenosine
triphosphate (ATP) [57, 114]. There are nine known isoforms of AC with similar
structures that span the plasma membrane twelve times and a single, more recently
discovered soluble type that varies in formation [57, 114, 115]. Their ability to form
different homodimers and heterodimers produces differing physiological effects by
way of cAMP production [114, 115]. cAMP aids in a regulatory purpose as a second
messenger, binding to various effector proteins to induce homeostatic changes
[114]. It is essential to the initiation of various developmental processes throughout
the body and in the Central Nervous System [115].
ACs are regulated by G Proteins [116]. The guanosine triphosphate (GTP)-bound
-subunit of Gs is reported to prompt activity in different isoforms of AC [116].
Furthermore, the subunits Gi, Go, and Gz are known to halt AC activity, based on
the isoform type [116]. y subunits are known to have initiating or abrogating effects
on ACs, also pendant on the isoform [116]. Ultimately, G-Coupled-Protein Receptors
maintain the ability to regulate the activity of ACs, and thus the synthesis of cAMP.
AC3 is an isoform of ACs reported to localize in various tissues within the body,
including, but not limited to the liver, pancreas, lungs, heart, and brain [117]. Within
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the brain, AC3 localizes on the ciliary membrane of mature neurons, and is an
effective and accepted neuronal primary cilia marker [8, 41]. It is also reportedly
expressed in primary cilia of mesenchymal descent, such as osteocytes, endothelial
cells, and fibroblasts [41].
Loss-of-function experiments have been utilized to explore the range of
functioning of AC3. Defects in AC3 are reported to elicit physiological and cognitive
impairments [57]. These include diseases such as depressive behaviors [118],
obesity [119], and impairments in olfaction (anosmia) [116]. Moreover, conditional
ablation of AC3 has been reported to elicit defects in learning and memory [120].
Collectively, the effects produced by the elimination of AC3 support the importance
of this enzyme in homeostatic functioning of different physiological systems.

vi.

Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common cause of dementia affecting a growing
number of adults in the world’s population. Commonly afflicting those aged sixty and older, this
pathology is associated with seven stages ranging from mild to severe symptoms; the onset
commonly starting with forgetting small tasks and its progression marked with a loss of
additional faculties, including cognitive impairment and damaged motor control [13]. It is a
devastating disease, and much is still unclear about its etiology and development. It is known
that early detection of AD has proven valuable in managing symptoms and promoting quality of
life, but diagnostic tools are still limited.
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The true etiology of AD is incompletely understood, and there are two main theories of its
cause: the cholinergic theory and the amyloid beta theory [121]. The premise of the cholinergic
theory of AD is that there is a deficit of cholinergic neurons in brains afflicted with AD [121]. It
is reported that choline acetyltransferase is impaired, resulting in a reduction of overall
acetylcholine in the brain [121]. This diminution would impede cognitive function by attenuating
neuronal excitability [122]. It is also reported that acetylcholinesterase is impacted by Amyloid
Beta [121]. Presently, the Amyloid Beta hypothesis is better understood and studied in AD [121],
thus the current thesis will focus on that hypothesis and its relevance to the design of this study.
Within the brain, Amyloid precursor protein (APP) is known to support neuronal growth and
repair [123]. Interestingly, deletion of this protein is not reported to elicit significant phenotypic
changes [124]. Secretases cleave APP into smaller peptides, including beta-amyloid [12]. High
levels of beta-amyloid, especially beta-amyloid-42, can lead to plaques within the brain, a
hallmark of AD [12]. It is still debated whether the accumulation of amyloid-beta plaques is
direct cause of AD, as plaques can be found in both demented and healthy aged brains [124], but
it is reported that the levels of beta-amyloid-42 in cerebrospinal fluid decrease with the
progression of AD, while increasing in the brain itself, indicating a reduction of expulsion of the
peptide [123, 124].
The protein tau is also associated with the development of Alzheimer’s disease [125]. Tau
stabilizes microtubules within the brain and neurons to aid in intracellular transport and stability
[125]. This results in maintenance and regulation of the microtubules. It is reported that amyloidbeta plays an important role in the development of hyperphosphorylated tau [125], although it is
not fully understood. In AD and other “tauopathies,” tau is hyperphosphorylated, thus
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destabilizing from microtubules and binding to itself [124, 125]. This deterioration results in
neurofibrillary tangles, and cell death [124, 125].
Conclusive diagnosis of AD necessitates postmortem analysis, although clinical evaluation
and examination of the presence of specific biomarkers can aide in detection in living patients
[126]. Currently, diagnosis of AD is based on a combination of factors, including progressive
cognitive decline, imaging Positron Emission Topography (PET), and Cerebrospinal Fluid (CSF)
markers [127]. Although early detection cannot eliminate the course of AD, it can allow for
proactive administration of treatments that can enhance the well-being of afflicted individuals
[126]. Electroencephalography (EEG) analysis has proven to be a noninvasive tool in evaluation
of AD, differentiating it from other dementias by showing variances in the data waveform [128,
129]. EEG is now used when AD is suspected, but introduction of this monitoring during routine
appointments as proactive screening has not yet been explored, including its use with
anesthetized patients.

vii.

Statement of Research Questions & Aims

This dissertation was divided into three major projects and sought to answer the
following three questions:

1. Is there a distinction between neuronal and astrocytic primary cilia in the
healthy and pathogenic mouse brain?
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The first goal of my dissertation research was to investigate the morphological dynamics
of astrocytic primary cilia, when compared to neuronal primary cilia [7]. This was
completed in the healthy and reactive brain to identify a previously unknown function.
My first aim was to compare astrocytic and neuronal primary cilia under reactive
conditions. Astrocytes and neurons embody a dichotomy of functioning in the brain. This
split suggests contrasting ciliary function in activities and behaviors. I hypothesized that
astrocytic primary cilia are implicated in reactivity and detectable by morphological
change, and used two models, a localized cortical injury model and a spontaneously
occurring audiogenic seizure model to investigate morphological alterations in cilia.
My results show that astrocytes maintain significantly longer primary cilia than those
of neurons in the healthy brain, with apparent differences in length between regions of
the hippocampus. Furthermore, these findings indicate that similar to hippocampal
neurons, astrocytes within the dentate gyrus are affected in mice exhibiting seizure
activity. I was unable to find astrocytic primary cilia with Arl13B staining in our cortical
injury model. IFT88 staining was also unable to indicate the presence of primary cilia.
We furthermore found an increased expression of Arl13B in injured tissue, with the
highest intensity proximal to the cortical wound. I determined that the ciliary shortening
may have been attributed to proliferation, but the alterations in Arl13B expression
suggested an unknown and possibly important role of this protein in tissue regeneration.

2. Does Arl13B regulate the development of reactive astrogliosis during
cortical lesion?
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Next, I sought to detect the contribution of Arl13B in brain injury and glial scarring.
Heightened understanding of the activity of astrocytic primary cilia and Arl13B under
reactive conditions establishes their importance in neuropathology and elucidates
potential therapeutic targets.
My second aim, founded on the data gathered from my first aim, was to
determine the role of Arl13B in cortical injury. Arl13B is known to direct neuronal
migration embryonically and additionally is implicated in Joubert’s syndrome [88, 110]. I
hypothesized that Arl13B is involved in the reparations following brain injury, including
ciliary destabilization and expression in the cell body. Specifically, we postulated that
the signaling mechanisms of Arl13B require absorption of the primary cilium to allow for
translocation of the protein into the cell body. Furthermore, we proposed that signaling
differences initiate cytoskeletal reorganization required for the morphological alterations
in reactive astrocytes.
My results showed that in four strains of mice, C57BL/6 Control, Arl13B-mCherry;
Centrin2-GFP (Gain-of-Function), Arl13B Loss-Of-Function, and Conditional IFT88UBC-Cre/ert2 Knockout, Arl13B expression levels were heightened near the cortical
lesion seven days post injury. GFAP expression levels were mixed between the strains
and did not reveal significant trends in heightened or decreased gliosis seven days post
injury. Our findings suggest that although Arl13B shows a clear pattern of heightened
expression proximal to the injury site, GFAP-positive astrocyte expression is not clearly
impacted. Although these findings do not negate the possible implication of Arl13B in
brain injury, they do not support its relevance in astrogliosis.
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3. Can EEG waveform analysis be used as a non-invasive means of early
diagnosis of AD prior to the onset of symptoms?
Lastly, I sought to determine if waveform analysis of electroencephalogram (EEG)
could be used to identify early hallmarks of Alzheimer’s Disease prior to the onset of
symptoms, subsequently providing the foundation for early diagnosis and proactive
therapeutic intervention.
My third aim was to investigate the electroencephalogram (EEG) patterns of a
mouse model of Alzheimer’s disease (AD) to determine if EEG recordings can be used
to determine the presence of the disease prior to the onset of symptoms. I hypothesized
that power spectral density and burst suppression density quantification could yield
relevant characteristics indicative of the dormancy and potential of AD while the subject
was anesthetized with isoflurane. Specifically, I postulated that examination of
differences in frequency bins associated with drowsiness and sleep (Alpha, Theta, and
Delta) and the percentage of suppressed epochs would differ in young (three-monthold) mice if carrying the mutation indicative of the future onset of the disease.
Our findings reveal that at 3 months of age, the time at which APP23 mice may
begin to develop the AD phenotype, APP mice display a lower relative percent of Delta
power spectral density than that of control mice during isoflurane exposure. Both Theta
and Alpha were shown to be higher in APP mice at this age. Burst Suppression Density
increased in all age ranges tested as the length of isoflurane exposure increased, and it
was significantly higher in young (3-4-month-old) APP23 mice when compared to
controls. These findings substantiate our hypotheses that there are statistically
significant differences detectable in the anesthetized EEG of a mouse model of AD.
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viii.

Rationale & Significance

A multitude of research focuses on the implication of primary cilia in disease.
They are known to be involved in obesity [57, 130], polycystic kidney disease [34, 68],
cognitive impairment [46], Joubert’s syndrome [103], and certain forms of cancer [92].
Current neuroscience research focused on primary cilia target neurons, determining
their transduction pathways and signaling dynamics. Yet, there is limited research
conducted on astrocytic primary cilia.
Astrocytes, which become more recognized every passing year for their
importance in neurological homeostasis and repair, possess primary cilia, yet research
pertaining to this subject is extremely limited. While several studies show that astrocytic
primary cilia are involved in the development of glioblastomas, there is incomplete
understanding of their function and role within the mature brain. During the progression
of reactive gliosis and development of conditions resulting in altered and potentially
impaired brain function, the role of astrocytic primary cilia is unknown. Comprehensive
understanding of the development and proliferation of reactive astrocytes requires
explication of the participation of astrocytic primary cilia under reactive conditions.
Clarification of the roles of astrocytic primary cilia could illuminate potential therapies
and enhance understanding by the scientific community.
Furthermore, the functionality of Arl13B, the accepted astrocytic primary cilia
marker, is poorly understood. This unique GTPase is known to promote ciliogenesis
[131], maintain GEF activity of Arl3 [102], and regulate Sonic Hedgehog Signaling [113].
However, its full range of functioning is unknown. Our initial investigations revealed
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alterations in protein expression of Arl13B proximal to cortical injury, indicated an
unexpected and previously unreported role of Arl13B in the regulation of brain injury.
Lastly and of great importance with consideration of the pathogenic brain, is the
need to determine early and non-invasive methods of diagnosis for Alzheimer’s disease.
AD accounts for more than half of case of dementia in the United States [12], but there
is currently no method of reversal of the disease. Once the disease has progressed, it is
reported to show abnormalities in EEG patterns and power spectral density [132], but
this research is limited. Additionally, it is not reported whether burst suppression can be
used as a diagnostic tool for this disease, especially prior to presentation of disease
symptoms. EEG analysis while under anesthesia is a cost-effective and minimally
intrusive means to examine brain activity. Power spectral density and burst suppression
density can be quantified algorithmically and visually from a patient’s EEG recordings,
allowing for different methods of analysis provide early diagnosis, thereby supporting
early intervention.
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Chapter 2

METHODS

i.

Transcardial Perfusions & Tissue Fixation

For transcardial perfusions, mice were first sedated with ketamine administration or
euthanized with carbon dioxide. Most 4-8-month-old adult mice were deeply
anesthetized by an intraperitoneal injection of ketamine (Ved Co, KetaVed, NDC
50989–161-06,)/xylazine (AKORN, NDC 59399–111-50) and monitored for nonresponsiveness. Lack of response was measured via absence of pedal reflex from a toe
pinch and absence of vertebral response via tail squeeze. After complete lack of
response was verified, specimen was stabilized with pins and the thoracic cavity was
exposed.
Several mice used for experiments were instead euthanized by carbon dioxide
administration, prior to immediate transcardial perfusion. After being individually placed
in an empty, clean cage, carbon dioxide administration would begin at a rate of 10-30%
of the chamber volume per minute. Twenty seconds following last breath, (roughly 3-4
minutes of exposure), the mice were removed for immediate perfusion and secured to
dissection pad.
Once secured and the thoracic cavity exposed, the right atrium was punctured with
surgical scissors and a catheter was inserted into the left ventricle. Ice cold Phosphate
Buffer Saline (PBS) was infused at a rate of 20 mL/min for approximately 5 minutes.
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This cleansed tissue from blood and prepared it for fixation. At least 20 mL of 4%
paraformaldehyde (PFA) (Sigma-Aldrich, 252,549-1 L) was then infused for preliminary
fixation.
Whole brains were extracted and placed in 4% PFA overnight, while rocking at a
slow rate at 4˚C. The following day, tissue was washed in and then placed in 30%
sucrose in PBS for dehydration purposes. Dehydration is an essential step of the
fixation process, which removes fixative and tissue fluid in preparation for staining.
Tissue remained rocking at 4˚C for approximately 48 hours or until tissue sank
completely. Following this fixation and dehydration process, tissue was then flash frozen
on dry ice and stored at -80˚C until sectioned.

ii.

Cryostat Sectioning

Prior to staining, flash frozen tissue was sectioned on a Leica CM3050 S cryostat to
30–35-micron sections at −18 °C. Tissue-tek optimal cutting temperature compound
(OCT) was used to mount tissue within the cryostat. Once fully secure, brain tissue was
sectioned from anterior to posterior, with attention to the location of injured cortex or
hippocampal regions. Desired regions were distributed into Eppendorf tubes filled with
cryoprotectant (3:3:4, glycerol: ethylene glycol: PBS) and maintained at -20˚C until use
for immunohistochemistry.
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iii.

Immunohistochemistry

To remove cryoprotect and residual OCT, thawed and sectioned tissue was first
washed 3 times at 10 minutes each in PBS at room temperature (RT) on an orbital
shaker. Large tissue pieces were transferred using baskets in a 12 well plate, while
small and fragile tissue pieces, like those from cortical injury studies, was transferred by
use of a Pasteur pipette in a 48 well plate. Tissue was then permeabilized in 0.5%
Triton in PBS (PBST) 3 times at 10 minutes each at RT to reduce background and
enhance the accessibility of cellular epitopes. Tissue was then blocked at RT in blocking
buffer: 10% donkey serum (Sigma, D9663–10 ML), 2% bovine serum albumin (SigmaAldrich, A7906-100G), and 0.1 M glycine (Apex, 18–109) in 0.5% PBST for 1.5 to 2
hours.
Following this staining preparation, tissue was then stained with a selection of the
primary antibodies listed in Table 1 while gently rocking overnight at 4˚C. The following
day, tissue was washed 3 times at 10 minutes each in 0.5% PBST and then incubated
with Alexa Fluor secondary antibodies 488, 546, and 647 at 1:500 dilution for 1.5 hours.
Stained tissue was then washed 1 time in 0.5% PBST and 2 times in PBS for 10
minutes each. Floating sections were then mounted to gelatin coated slides with DAPI
nuclear stain, and coverslips were secured with clear nail polish. Slides were stored at 20˚C until imaging with confocal microscopy.

iv.

Seizure Phenotyping
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To phenotype mice displaying spontaneous audiogenic seizures, Arl13B-mCherry;
Centrin2-GFP transgenic mice (Arl mice) were monitored for seizure-like behavior
graded with a modified Racine scale (Table 2). The Arl mice have a hybrid FVB; BALB;
C57BL/6 background. Strains of FVB mice are known to show predispositions to
audiogenic seizures [133-135]. This suggests that the seizure activity found in our
population of Arl mice may have been a of the partial FVB background.
Mice were observed individually 10 times over 2 weeks. To determine presence of
seizure activity, mice were individually removed from their home cage and placed in a
clean, empty cage for 30-60 seconds. This activity was usually enough to initiate
seizure activity. Afflicted animals were marked with an animal marker and then returned
to littermates in their home cage. Following the 2-week initial period of observations,
mice were checked weekly throughout the duration of the experiment to determine
phenotypic changes and re-mark as necessary.

v.

EEG/EMG Recording

To verify that the epileptic-like behavior being observed was in fact seizure activity,
mice underwent EEG/EMG surgeries and recordings. Equivalent numbers of seizure
and non-seizure 4-8-month-old mice were further divided into equally sexed groups.
This age range was used to provide the opportunity for the onset of seizure activity,
which was not displayed in younger mice. Mice were individually anesthetized with 1.5–
3% isoflurane (Henry Schein, NDC 11695–6776-2). Once fully sedated, mice were
stabilized in a stereotaxic frame (Kopf instruments) by non-rupture ear bars. Once
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secured, isoflurane anesthesia was maintained and mice were prepared for surgery by
hair removal and skin sterilization with alcohol and 4% chlorhexidine (Phoenix, NDC
57319–612-09). Ophthalmic ointment (Solutions, Alta lube Ointment, X0020S6KF) was
applied to prevent corneal drying. An injection of 1 mg/kg lidocaine (Phoenix, NDC
57319–533-05) was administered to the scalp and 5 mg/kg carprofen (Putney, NDC
26637–521-02) was injected subcutaneously in the dorsal region.
A single incision was made along the sagittal suture and skin was pulled laterally.
The surface of the cranium was dried with sterile cotton swabs. The EEG/EMG headmount (Pinnacle Technology Inc., Cat # 8201) was then fixed to the cranium with
VetBond (3 M VetBond, 1469SB) and 3 holes were drilled into the skull with a sterile 24gauge needle. Micro-screws (Pinnacle Technology Inc., Cat # 8209) were used to
further secure the head mount with Resin (Resin lab, SEC 12334GR) positioned
between the screws and head-mount prior to tightening.
Two probes attached to the back of the head-mount were inserted into the
spinotrapezius of the cervical region of the mouse. Skin was then sutured around the
base of the implant as needed. Following this, the head-mount and screws were
secured with dental cement. Recovering mice were allowed to rest on a heating pad
until fully active. Mice were given 5 mg/kg carprofen injections (Putney, NDC 26637–
521-02) or meloxicam tablets in cage (Meloxicam (233634, BioServe, MD275-0125) as
analgesia for 2-3 days following surgery and monitored for weight or health fluctuations.
After a recovery period not exceeding 1 week, mice were secured with EEG/EMG
Pinnacle Technology recording equipment and monitored for 48 hours. During this time,
mice were housed in individual enclosures and allowed food and water ad libitum.
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Recording equipment did not interfere with the free movement of animals. Mice were
sacrificed via transcardial perfusion within 24 hours of the completion of their recording.

vi.

Isoflurane Administration

Approximately one week following EEG/EMG head-mount surgery, mice were
secured with Pinnacle EEG/EMG recording equipment. Mice were allowed to move
freely for at least five minutes and then placed [singularly] into a chamber filled with 3%
isoflurane gas. Mice remained in the isoflurane chamber for 15 minutes before being
removed and allowed to rouse. Times were recorded and added to parallel virtual file
system (pvfs) files to support accurate waveform analysis. All mice were monitored until
they fully righted and showed normal activity.

vii.

Sirenia Software Analysis

Sirenia Seizure Pro software (Pinnacle Technology Inc. Version 1.8.3) was used to
identify seizure activity. Automated software was used to identify seizure-like electrical
activity greater than 5 seconds. All artifacts were confirmed visually and then compared
for sexual bias, time of day, length of event, EEG and EMG amplitude. Seizure behavior
was characterized by frequent and chaotic EEG peaks displaying high power. This
activity was often correlated with heightened EMG activity.
Sirenia Sleep Pro scoring software (v. 2.1.0) was used to examine EEG/EMG
recordings of four Arl mice for the first twenty-four hours of recording. Mice were gender
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balanced, with two having been phenotyped as displaying seizure activity and two
without prior knowledge of this behavior. To maintain consistency with analytics from
Sirenia, power was set to Sleep Pro defaults as follows: Alpha 8-13; Beta 13-30;
Gamma 35-44; Delta 0.5-4; and Theta 4.5-8.5. Activity was first scored into Wake and
NREM via cluster scoring of EEG2 Delta against EMG 50-150. Activity was then visually
confirmed and scored by the following criteria: Wake was associated with moderate to
high EMG activity; NREM maintained low EMG activity and high EEG power; REM
displayed low EMG activity, but low power and high frequency.

viii.

Confocal Imaging & ImageJ Analysis

Tissue stained via immunohistochemistry was imaged with a Nikon A1R HD25
microscope. Tiled and non-tiled Z-stacks were collected while imaging hippocampal
regions and/or cortical injury of different murine strains. Variation in tissue quality and
antibody binding required small variations in visualizing controls to enhance picture
quality. 2-4 Z-stacks were acquired of each cornu ammonis 1 (CA1), cornu ammonis 3
(CA3), and dentate gyrus (DG) regions of the hippocampus (Figure 5). 2-4 images of
the ipsilateral and contralateral hemispheres were acquired in support of injury analysis.
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CA1

CA3
DG

Figure 5: Architecture of the Hippocampus. Astrocytic and neuronal primary cilia were measured in the
CA1, CA3, and DG regions of the hippocampus. Squares represent locations in which cilia were
measured. Distinguishable astrocytic cilia were measured within the white regions of the squares.
Neuronal primary cilia were measured within the black, cellular localizations within the squares.

Collected images were then quantified with Fiji ImageJ Analysis (ImageJ 1.52f,
Java 1.8.0_172 (64-bit). Analysis consisted of ciliary measurements and protein
intensity analysis. To verify that only Arl13B-positive astrocytic cilia were measured,
distinguishable cilia in the tissue surrounding to the cellular localizations of CA1, CA3,
and DG were used only (Figure 5). Distinguishable AC3-positive neuronal cilia were
measured directly within the gathering of cells in hippocampal regions. Due to the
limited number of Arl13B-positive cilia in CA1 and CA3, all fully identifiable astrocytic
cilia were measured and used for analysis in these regions. For Arl13B-positive cilia in
the DG and cortex, and all AC3-positive cilia, there were significantly more distinct cilia.
Thus, approximately 50 cilia were measured per image in these regions.
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Astrocytic reactivity was identified via somatic differences of astrocytes within the
hippocampus or cortex. GFAP expression was elevated in these cells, as measured
with GFAP intensity, and reactive astrocytes encompassed a larger region, extending
processes into the territory of neighboring astrocytes. GFAP and Arl13B protein
intensity was quantified with a plot profile of ImageJ pixel intensity analysis of 3-4 500micron lengths per region of the brain and then averaged per site.

ix.

Cortical Injury Model

Experimental mice were individually sedated with 1.5–3% isoflurane (Henry Schein,
NDC 11695–6776-2). Once unresponsive, mice were secured in a stereotaxic device
(Kopf instruments) by non-rupture ear bars. While under anesthesia, mice were
prepared for surgery by hair removal and skin sterilization with alcohol and 4%
chlorhexidine (Phoenix, NDC 57319–612-09). Corneal drying was prevented by the
administration of ophthalmic ointment (Solutions, Alta lube Ointment, X0020S6KF).
1 mg/kg of lidocaine (Phoenix, NDC 57319–533-05) was injected into the scalp and
5 mg/kg carprofen (Putney, NDC 26637–521-02) subcutaneously administered posterior
to the thoracic cavity.
A small sagittal suture was made to expose bregma and lambda, the intersections of
the sagittal suture and coronal and occipital suture respectively . Cranial bones were
dried and cleansed with sterile cotton swabs or gauze. A single hole was drilled 1-3 mm
lateral to the sagittal suture and approximately 3 mm anterior to lambda. A sterile
needle was then secured to the stereotaxic frame and lowered to the meninges. The
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needle was then inserted 3 mm deep into the brain by the stereotaxic arm. This
insertion was repeated in triplicate to ensure effective cortical injury. The incision was
then sutured, and mice were allowed to recover on a heating pad. They were monitored
until fully active and given meloxicam (233634, BioServe, MD275-0125) as analgesia
for 3 days following surgery. Mice were sacrificed via transcardial perfusion within one
week following surgery.

x.

Brainstorm Analysis

Power spectral density and Phase Amplitude Coupling were quantified using
Brainstorm software (version 3.220115) [35] via the MATLAB platform (version
R2021b_9.11.0.1809720). Brainstorm is a graphical user interface (GUI) created for
analysis of EEG waveform [35]. EEG recordings of APP23 mice undergoing exposure to
isoflurane anesthesia were extracted by Sirenia sleep pro software and converted to
EDFs. EDF files were uploaded into brainstorm to be filtered and processed.

Filtering
All EEG recordings incorporated into Brainstorm underwent three forms of
processing. First, DC offset was removed to reduce offset from digitization [136]. A band
pass filter [136-138] was then applied between 0.5 and 199 Hz (Butterworth filter, low
pass order 4, high pass order 3). Lastly, a notch filter [136, 139] was applied at 60 and
120 Hz with a bandpass of 1, to remove power line noise and its harmonics.
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Power Spectral Density

Brainstorm was then used to apply Welch’s Power Spectral Density algorithm
[140, 141] to the filtered EEG files to quantify the density of the power frequencies.
Powers were identified based on the following parameters: Delta: 0.5-4; Theta: 4-8;
Alpha: 8-13; Beta: 13-30; Gamma: 30-200 [142]. Relative percentages of frequencies of
PSDs averaged across bins per strain with respect to age and compared based on
length of isoflurane exposure. Statistical significance was set as a P value of less than
0.05 via the Mann Whitney Test.

Phase Amplitude Coupling

Phase Amplitude Coupling (PAC) was calculated via the Brainstorm plugin of MATLAB.
A high bandwidth of 50-120 Hertz was used as a nesting frequency against a low
bandwidth of 3-10 Hertz, to compare Gamma and Theta, respectively [143, 144].
Statistical significance of maximum PAC was set as a P value of less than 0.05 via the
Mann Whitney Test.

xi.

Burst Suppression Density

Sirenia sleep pro software (version 1.0.3) was used to visually score eeg1 and eeg2
for periods of suppression by manually scoring epochs. First, time of isoflurane
exposure was logged onto EEG recordings. After being sectioned into five-second
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epochs, time intervals of one minute were compared and contained epochs were scored
as suppressed or nor suppressed (Figure 6). Identification of suppressed epochs was
quantified by five-second periods with little or no electrical activity as compared to
epochs containing bursts of activity, indicative of neuronal firing. Total number of
suppressed epochs were divided by the total number of epochs per minute (12) and
multiplied by 100 to give the density of suppression [145]. All scored epochs were
confirmed by a second scorer.

A

B

Figure 6: Identification of Suppressed Epochs. Sample of 60 seconds of raw EEG2 recording showing
burst suppression pattern (A) sectioned into 5 second epochs (B) scored with red to indicate suppression
(B). Y Scale bar: 50 µV.; X time scale: 5 seconds.
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xii.

Mouse Strains

FVB/N
The Friendly Virus B mouse (FVB) strain acquired from Jackson laboratories
(Stock number: 001800) is widely used in scientific research. Known for fecundity and
delivery of large litters, this strain has proven useful in genetic manipulation and
analysis [146]. Predisposition to spontaneous audiogenic seizure activity has been
reported in this strain [133-135]. This activity is usually initiated by mild to moderate
stimuli, such as tail tattooing, clipping, and loud noises [133]. FVB mice were used as
a control for ciliary length comparisons in these studies.

C57BL/6J
The C57BL/6J (Jackson lab stock number 000664) murine strain is one of the
most commonly used strains in research [147]. This strain is generated to support a
variety of studies, especially transgenic and knockout studies, and is the foundation of
many investigations [148]. The C57BL/6J strain was used as a control for ciliary length
comparisons and cortical injury studies.

Arl-mCherry; Centrin2-GFP
The Arl-mCherry; Centrin2-GFP strain (Arl mouse) can also be attained from
Jackson Laboratories (stock number 027967). This is a hybrid strain with a mixed
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background of FVB, BALB/c, and C57BL/6 strains (Jackson Laboratory). This strain was
first generated by Bangs et al. in 2015 to investigate the expression of primary cilia
during development [52]. In the following studies, the Arl strain was used to study ciliary
length, overexpression of Arl13B, spontaneous seizure activity, and cortical injury.

UBC-Cre-ER2
UBC-Cre-ER2 mice (stock number 007001) acquired from Jackson Laboratories
can be crossed with mice containing loxP sites to produce a tamoxifen inducible
knockout of the floxed gene. This strain was crossed with IFT88 floxed and Arl13B
floxed mice to produce a hybrid that could allow for selective gene knockout.

IFT88flox/flox
IFT88flox mice (stock number 022409) were acquired from Jackson laboratories
and crossed with UBC-Cre-ER2 mice to produce IFT88; UBC hybrid strain. IFT88floxed
mice contain loxP sites around exons 4-6 of the IFT88 gene essential for intraflagellar
transport and structure of the cilium (Jackson Laboratory). The hybrid cross of IFT88;
UBC knocks out IFT88, resulting in ubiquitous ablation of primary cilia [50].

Arl13Bfox/flox
Arl13Bfloxed mice (stock number 031077) were acquired from Jackson
laboratories and crossed with UBC-Cre-ER2 mice to produce Arl13B; UBC hybrid strain.
Arl13Bfloxed mice contain loxP sites around exons 2 of the Arl13B gene (Jackson
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Laboratory). The hybrid cross of Arl13B; UBC knocks out Arl13B, resulting in ablation of
this GTPase in primary cilia and the surrounding tissue [149].

APP23
APP23 mice (stock number 030504) were acquired from Jackson laboratories.
Both non-carriers and mutants hemizygous for Thy-1 APP were used as controls and
AD models, respectively. These mice were transgenically modified to display an
overexpression of the human amyloid precursor protein, which allows for the
manifestation of AD-like symptoms starting at 3-months of age and progressively
worsening [150].
xiii.

Data Analysis

All data quantified with ImageJ were analyzed and graphed with GraphPad Prism
(9.3.1) and JMP statistical analysis software. Analyses were completed with unpaired
Student’s T-Test with Welch’s correction, one-way ANOVA with Bonferroni correction,
density analysis, Kolmogorov-Smirnov test, and Mann-Whitney test [151]. Significance
was denoted as follows: a p value less than 0.05 (*), less than 0.01 (**), and less than
0.001 (***). Data was presented as mean ± standard error of the mean.
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CHAPTER 3

PRIMARY CILIA LENGTH VARIANCE

i.

ASTROCYTIC VERSUS NEURONAL PRIMARY CILIA

Astrocytes and neurons present a functional diversity in the brain [6]. Astrocytes are
supportive cells, which participate in a wide range of functioning and maintain
proliferative capacity throughout maturity [4]. They are highly heterogenous and
maintain versatility in pathogenic conditions. Neurons are electrically excitable cells
primarily acting in signal transduction, which lose mitotic ability after differentiation [152].
Neurons rely on astrocytes to synapse with one another and succumb easily to damage
[1, 61, 62, 70, 153].
Although both astrocytes and neurons exhibit primary cilia, their functional
differences manifest in contrasting roles for this organelle. Morphologically, neuronal
primary cilia are significantly longer than astrocytic cilia in the hippocampus;
approximately 5.5 microns compared to roughly 3.0 microns respectively [7]. In order for
ciliated vertebrate cells to mitose, the primary cilium must first retract into the cell to free
the centrioles for translocation and spindle fiber production needed in anaphase [9]. The
proliferative capacity of astrocytes indicates the potential requirement of ciliary
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retraction, while the role of neurons as predominant signal transducers in the brain
without mitotic capability suggest the structural logic in their ciliary length.
Astrocytic and neuronal primary cilia require different ciliary markers for effective
antibody labeling. Astrocytes are known to express Arl13B in their ciliary membrane at
maturity [8, 48]. Alternative antibodies that effectively stain astrocytic cilia in both in vitro
and in vitro conditions are unknown. Neuronal cilia are known to express several ciliary
proteins and thus have multiple ciliary markers that are effective under different
conditions. These include AC3, SSTR3, 5-HT6, and MCHR1 [48].
It has been reported that astrocytes and neurons display differential ciliary protein
levels at immaturity. In 2014, Kashara et al. reported that although colocalization of
Arl13B and AC3 can appear in cilia of P10 mice, astrocytes at P56 predominantly
express Arl13B and neurons express high levels of AC3 [8]. The distinction between
ciliary protein expression indicates functional variations between these cell types.
We hypothesized that the functional differences between astrocytes and neurons
manifest in morphological differences in their primary cilia. We thus used
immunohistochemistry, confocal microscopy, Arl13B antibody and AC3 antibody to
visualize cilia. We focused on regions within the hippocampus to support quantitative
imaging with regional consistency. We compared 3 strains of mice: C57BL/6, FVB, and
Arl13B-mCherry; Centrin2-GFP (Arl mice).
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Figure 7: Regional Variance of Primary Cilia Length in the Hippocampus. Figure sourced from
Sterpka et al., 2020 [6]. Arl13b-positive and AC3-positive primary cilia of Arl mice are longer than those of
FVB/N and C57BL/6 wildtype mice. a-c, g Arl mice had longer Arl13b-positive primary cilia than control
mice in the hippocampal CA1, CA3, and DG regions. a Arl mice, b FVB/N controls, c C57BL/6 controls.
Representative images were taken from the CA1 region. Scale bar, 5 μm. g Comparison of Arl13b + cilia
length in the hippocampal CA1, CA3, and DG of three mouse strains. Arl mice, N = 8; FVB/N mice, N = 5;
C57BL/6, N = 4. Cilia number: Arl mice: 399, 230, and 435; FVB/N: 213, 146, and 254; C57BL/6: 144,
118, and 116. Data were compared with one-way ANOVA test with post hoc Tukey test. CA1: F(2, 753)
=307, p < 0.001; CA3: F(2, 491) = 251, p < 0.001; DG: F(2, 802) = 241, p < 0.001. (d-f, h) Arl mice had
longer AC3-positive primary cilia in three subregions in the hippocampus. d Arl mice, e FVB/N
controls, f C57BL/6 controls. Scale bar, 5 μm. h Comparison of AC3+ primary cilia length in hippocampal
CA1, CA3, and DG regions. Arl mice, N = 4; FVB/N, N = 5; C57BL/6, N = 3. Cilia number: Arl mice, 403,
471, and 527; FVB/N mice: 386, 343, and 555; C57BL/6: 202, 422, and 180. Data were analyzed with
one-way ANOVA test with post hoc Tukey test. CA1: F(2, 988) = 58, p < 0.001; CA3: F(2,
1233) = 40, p < 0.001; DG: (2, 1259) = 21, p < 0.001. i CDFs and histogram density of cilia length show the
distribution differences of Arl13b-positive cilia length in different hippocampal regions of the three mouse
strains. j CDFs and histogram density of cilia length demonstrate the distribution differences of AC3positive cilia length in different regions of three mouse strains. Legends sourced from Sterpka et al, 2020
[6].
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Confocal imagery revealed length differences between Arl13B-positive and AC3positive primary cilia, regional variations of length within the hippocampus, and even
strain variance (Figure 7: A-F). Measurements revealed that Arl13B-positive cilia were
significantly shorter than AC3-positive cilia in all regions of the hippocampus for
C57BL/6 and FVB mice (Figure 7: G-H). Arl mice displayed significantly longer
astrocytic and neuronal cilia in all regions than both other strains, suggesting an
overexpression of Arl13B (Figure 7: G-H). Density comparison analysis and cumulative
distribution functions were used to verify significance (Figure 7: I-J).

Figure 8: Arl13b Elongates Cilia length in Primary Cultures. Figure sourced from Sterpka et al, 2020
[6]. l Arl13b-positive cilia in primarily cultured astrocytes were significantly longer than those derived from
C57BL/6 mice (***, p < 0.001, unpaired Student’s t-test). Data were collected from 6 Arl cultures, 5
C57BL/6 cultures. Cilia number: Arl mice, 50; C57BL/6 mice, 57. m CDFs and density comparisons
demonstrate the differences in Arl13b-positive cilia length between Arl mice and C57BL/6 mice. n AC3positive cilia in primarily cultured cortical neurons (~ 10 days in vitro) were significantly longer than those
derived from C57BL/6 mice (***, p < 0.001, unpaired Student’s t-test). Data were collected from 6 Arl
cultures, 6 C57BL/6 cultures. Cilia number: Arl mice, 87; C57BL/6 mice, 87. o CDFs and density
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comparisons demonstrate the differences in AC3-positive cilia length between Arl mice and C57BL/6
mice [6]. Legends sourced from Sterpka et al, 2020 [6].

To substantiate morphological variances between Arl and C57BL/6 mice, primary
cultures of astrocytes and neurons were harvested to investigate variations in Arl13Bpositive primary cilia and AC3-positive primary cilia respectively. Cortical tissue from
day old pups was used to create pure cultures. Immunocytochemistry uncovered
significant length differences in primary cilia, with Arl mice exhibiting significantly longer
astrocytic and neuronal cilia lengths (Figure 8: L-O).
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Figure 9: Primary Cilia Length in Different Strains of Mice. Figure sourced from Sterpka et al, 2020
[6]. Regional cilia length variations in the hippocampal CA1, CA3 and DG in Arl mice, FVB/N and
C57BL/6 mice. a Arl13b-positive cilia in hippocampal regions of Arl mice were significantly shorter cilia in
the DG than in CA1 or CA3 (***, p < 0.001, unpaired Student’s t-test). N = 8 mice. Cilia number: 399, 230,
and 435. b Arl13b-positive cilia of FVB/N mice had no significant differences in length among
hippocampal CA1, CA3, and DG regions. N = 5 mice. Cilia number: 213, 146, and 254. c Arl13b-positive
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cilia of C57BL/6 mice had no significant differences in length among the hippocampal CA1, CA3, and DG
regions. N = 4 mice. Cilia number: 144, 118, and 116. d AC3-positive cilia in the hippocampal DG region
of Arl mice were significantly (***, p < 0.001) shorter than in the CA1 and CA3 regions, and significantly
shorter in the CA3 than in the CA1 (*, p < 0.05). N = 4 mice. Cilia number: 403, 471, and 527. e AC3positive cilia in hippocampal DG regions of FVB/N control mice were significantly (***, p < 0.001) shorter
than in the CA1 and CA3 regions. N = 5 mice. Cilia number: 386, 343, and 555. f AC3-positive cilia in
hippocampal DG regions of C57BL/6 mice were significantly (***, p < 0.001) shorter than in the CA1 and
CA3 regions. N = 4. Cilia number: 202, 422, and 180. Data were analyzed with one-way ANOVA with post
hoc Tukey test. Arl13b: Arl strain: F(2, 1061) = 11.05, p < 0.001; FVB: F(2, 610) = 0.5850, p = 0.4632;
C57BL/6: F(F(2, 3775) = 0.7700, p = 0.4632; AC3: Arl Strain: F(2, 1398) = 213.6, p < 0.001; FVB: F(2,
1281) = 93.82, p < 0.001; C57BL/6: F(2, 801) = 62.96, p < 0.001

Remarkably, FVB and C57BL/6 mice did not display any regional differences in
Arl13B-positive ciliary length (Figure 9). Arl mice showed a marked decrease in length
of cilia residing in the dentate gyrus. AC3-positive cilia displayed shortened lengths in
the dentate gyrus of all 3 strains, and a moderate shortening in CA3.
Clear morphological differences exist between Arl13B- and AC3-positive cilia,
supporting the hypothesis of functional diversity. The maintained heterogeneity of
astrocytes warrants the need for shortened cilia to accompany proliferation and cellular
migration. The extended and stable cilia of neurons support the signaling nature of
neurons. Regional variations in the hippocampus manifesting in a variance of ciliary
length may indicate locale-based functional variance. The variation in ciliary length
based on murine strain was likely due to an overexpression in the Arl mouse based on
the CAGG promoter location of fusion protein. There were no obvious differences
between the two control strains.

ii.

EFFECT OF SEIZURES ON PRIMARY CILIA

Reactive astrocytes are reported to develop during seizure activity, although their
complete role in countering or propagating seizures remains unclear [3, 154-156]. The
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reactivity of astrocytes is a hallmark of the epileptic brain, but it is unknown whether
reactive astrocytes are simply a homeostatic response to aggravated conditions or
perpetuators of seizure activity. The basic elements of the development of reactive
gliosis indicate toxicity present in the brain requiring demarcation of healthy tissue or
altered astrocytic function, correlative with variations in morphology [1, 153]. Contrasting
views suggest that the altered expression and function of astrocytes yield seizure
activity

by

reduction

of

synaptic

maintenance,

and

subsequent

excess

of

neurotransmitters [3, 154, 156].
Scientific investigations have reported that seizures induced with piloporcaine
and kainic acid disrupt neuronal primary cilia lengths [157, 158], but these studies are
limited in their investigation of different types of primary cilia in the brain, as well as the
type of seizure induction. One study generalized glial cilia with use of Arl13B and GFAP
antibodies and analyzed their lengths after seizure induction, but no differences were
reported [157]. This study showed that neonatal seizure activity was enough to disrupt
neuronal ciliary lengths in the developing mouse [157]. Nonetheless, there are presently
no scientific studies investigating the response of astrocytic primary cilia to seizure
activity.
We hypothesized that astrocytic primary cilia were implicated under epileptic
conditions. Under the assumption that glial cells were overlooked in past research
based on the generalized focus on neuronal cilia, we postulated that the importance of
astrocytic function, signaling, and proliferation under reactive conditions would result in
ciliary morphological alterations. Specifically, we expected a shortening of cilia in
astrocytes to support the need of ciliary resorption
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A percentage of FVB/N strain of mice is reported to display spontaneous,
audiogenic seizure activity [133-135]. This epileptic activity is initiated by mild
manipulation of the mouse, including cage changes and loud noises [133-135].
Research has shown that mice exhibiting convulsive behavior suffer an array of
physiological disturbances, including: lower weights [135], decreased motor neuron
function [135], lower neuronal densities [134], astrocyte hypertrophy [133], and necrotic
neuronal tissue [133].
The Arl13B-mCherry; Centrin2-GFP strain we acquired from Jackson Laboratory
is a hybrid cross, including FVB/N in its background. Cage changing revealed that a
high portion of our population of Arl mice displayed seizure activity. This occurrence of
epileptic activity presented a unique opportunity for us to investigate the effect of
repetitive, spontaneously occurring seizures on primary cilia. We thus pursued
verification and immunohistochemical analysis of these mice.
To first determine the percentage of mice displaying a seizure phenotype, all
animals were individually observed on a daily and then intermittent basis. I found that
42% of our population displayed seizure activity (Figure 10). To substantiate that the
convulsive behaviors were in fact seizures, we next performed EEG/EMG probe
implants and 48-hour recordings on cohorts of control and seizure Arl mice. Recordings
were analyzed with Sirenia Seizure Pro Software (Pinnacle Technology), which verified
that chaotic electrical activity corelated with seizure events (Figure 10).

53

Results

A

D

Non-Seizure
EEG

All
EMG

200 uV

B

10 sec

Male

EEG

4
***

3
2
1
0

EMG

200 uV

Racine Score

C

Seizure

Female

Non-Seizure Seizure
10 sec

E

Non-Seizure

GFAP

Seizure

GFAP

Figure 10: Arl13B-mCherry; Centrin2-GFP Mice Exhibit Spontaneous Seizure Activity. Figure
sourced from Sterpka et al., 2020 [6]. Arl mice exhibit a high incidence of spontaneous seizure
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activity. a Naturally occurring seizures occur in a large proportion of Arl mice. Blue: non-seizure; red:
seizure. N = 78. b Both male and female Arl mice had seizure activity. Males had 16 mice out of 33 total
exhibiting seizures. Females had 17 seizure mice out of 43 total. c Arl seizure mice exhibit a high Racine
score on average. 15 non-seizure mice were compared with 10 seizure mice. ***, p < 0.001, unpaired
Student’s t-test. d EEG/EMG recordings confirmed the occurrence of seizures among Arl mice. Epileptic
waveform of EEG/EMG recording verified seizure activity in a mouse grading high on Racine score
(bottom), compared to non-seizure Arl mice which lacked high-amplitude EEG/EMG waves
(top). e Immunofluorescence staining of non-seizure and seizure brain tissue shows drastically elevated
GFAP expression in tissues from seizure mice, indicative of astrocyte reactivity. Top, DG; bottom, CA1
region. Scale bar, 50 μm

Immunohistochemistry using Arl13B and AC3 antibodies revealed a shortening
effect of seizure activity on primary cilia (Figure 11). AC3-positive primary displayed a
shortening in all regions of the hippocampus. Remarkably, Arl13B-positive primary cilia
showed the strongest shortening in the Dentate Gyrus, with limited effects in CA1 and
CA3.
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Figure 11: Spontaneous Seizure Activity Shortens Primary Cilia in the Hippocampus. Figure
sourced from Sterpka et al., 2020 [6]. Naturally occurring seizures reduce the length of AC3-positive and
Arl13b-positive primary cilia in the hippocampus. a-b Arl13b-positive cilia in the hippocampal CA1 and DG
regions of Arl seizure mice (b) were shorter than those of non-seizure Arl control mice (a). Scale bar:
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5 μm. c the length of Arl13b-positive cilia in the CA1 and DG regions, but not in the CA3 region, was
significantly shorter in Arl seizure mice than in Arl non-seizure mice (***, p < 0.001, unpaired Student’s ttest). Arl non-seizure controls, N = 4; Arl seizure mice, N = 5. Cilia number: non-seizure mice: 160, 130,
and 253; Seizure mice: 180, 131, and 183. d CDFs and histogram density comparison present the length
of Arl13b-positive cilia in the CA1, CA3, and DG regions. e-f AC3-positive cilia in the CA3 region of Arl
non-seizure control mice (e) and Arl seizure mice (f). Scale: 5 μm. g Cilia length comparison revealed the
shortening of AC3-positive cilia in three hippocampal regions of seizure mice (CA1: *, p < 0.05, CA3:
***, p < 0.001, DG: *, p < 0.05, unpaired Student’s t-test). Non-seizure controls, N = 4; seizure mice, N = 5
animals. Cilia number: non-seizure mice: 403, 471, and 527; seizure mice: 374, 294, and 375. h CDFs
and histogram density show AC3-positive cilia length in the hippocampal CA1, CA3, and DG
regions. i Seizure does not significantly affect the percent of Arl13b-positive cilia in the DG. Data collected
from 3 non-seizure and 3 seizure Arl mice. Cell number: control: 185; seizure: 196. Cilia number: control:
64; seizure: 51. n.s. not significant, with unpaired Student’s t-test. j Seizure does not significantly affect
the percent of AC3-positive cilia in the DG. Data collected from 3 non-seizure and 3 seizure Arl mice. Cell
number: control: 292; seizure: 414. Cilia number: control: 221; seizure: 282. n.s. not significant, with
unpaired Student’s t-test. k Centrin2-GFP expression in hippocampal regions in Arl seizure mice had no
significant difference with that in Arl non-seizure mice. Centrin2 imaging density over 50 μm 2 regions per
mouse was calculated. Data were collected from 3 non-seizure and 3 seizure Arl mice. p = 0.6, 0.9, and
0.5 respectively with unpaired Student’s t-test

The shortening of astrocytic primary cilia in this study may differ from a singular,
previous report of no change [45] due to the form of seizure induction. For methods of
control and consistency, many researchers use piloporcaine or kainic acid to initiate
seizure activity [157, 158]. The murine model we used displayed spontaneous and
repetitive seizure activity without any occurrences of death or disruptions to fecundity.
The sustained and repetitive seizure may be the basis of the ciliary shortening observed
in astrocytes. The duration of time during which consistent seizure activity occurred
could also be linked to heightened reactivity and thus a more observable effect in
astrocytes.
It is surprising that seizure activity affected astrocytic primary cilia more
drastically in the DG than any other region of the hippocampus (Figure 11). It is
possibly due to the functional difference of this region compared to the other parts of the
hippocampus. It has been reported that piloporcaine induced epilepsy can result in
astrocyte degeneration specifically in the DG, which indicates a conditional difference of
astrocytes within this region [159]. Adversely, astrocytes in the DG are reportedly of a
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similar group and number as in CA3 [160], which further emphasizes the distinctiveness
in this result. Different means were used to verify the accuracy of this result, and it was
repeatedly substantiated. This surprising result suggests a functional difference of
astrocytic primary cilia in the DG.

iii.

EFFECT OF CORTICAL INJURY ON PRIMARY CILIA

Astrocytes are crucial responders to traumatic and toxic events in the brain. They
assist with recovery of the injured Brain Blood Barrier [161], maintain the health and
integrity of neuronal synapses upon damaged conditions [1, 2, 4, 153], and manage the
creation of the glial scar around lesioned tissue [79, 162]. Glial scarring is a reparative
event restricted to the central nervous system that is a hallmark of brain injury [163].
Wounded and toxic tissue is surrounded by a mass of astroglia, microglia, and cellular
matrix to impede migration of harmful debris and toxic substances, thereby protecting
certain functionality in healthy tissue [162].
The inherent role of astrocytes in neurological pathology supported the
development of our hypothesis that astrocytic primary cilia must also function in and be
implicated in the development of astrogliosis. Ciliary research has demonstrated that
primary cilia are integral to signaling in physiological health and certain pathologies
[164]. We thus hypothesized that astrocytes must (1) shorten and withdraw their primary
cilia in order to proliferate and (2) use their primary cilia in signaling towards producing
reparations guided by alterations in astrocytic morphology. Similarly, neurons, being
vulnerable in their morphological rigidity, are particularly sensitive to injury. They lack
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proliferative capacity and easily succumb to a toxic environment. We hypothesized that
their primary cilia, acting primarily as signaling centers, would also be implicated during
the development of reactivity and potential destruction of neurons.
Results
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Figure 12: Cortical Injury Shortens Neuronal Primary Cilia. Figure sourced from Sterpka et al., 2020
[6]. Tissue injury decreases the length of AC3-positive primary cilia. a AC3-positive cilia were shortened
close to injured tissues. Scale bar: 5 μm. Top, non-injured tissues; bottom, injured tissues. b the
frequency of AC3-positive cilia was not changed between injured and non-injured tissues (n.s. not
significant, unpaired Student’s t-test). c Comparison of AC3-postive cilia lengths reveals significant
decrease in cilia length proximal to injury sites compared to injured tissues (*** p < 0.001, unpaired
Student’s t-test). N = 5, C57BL/6 mice. Non-injured sites were from opposite hemisphere of the injury site
of the same animals. Cilia number: non-injured sites: 271; injured sites: 326. d CDFs and density
comparison indicate the shortening of AC3-positive cilia length near to injury sites

We found that neuronal primary cilia displayed a significant shortening proximal
to injured cortical tissue (Figure 12). This aligned with a heightened expression of
GFAP shown by reactive astrocytes close to the injury (Figure 13). Curiously, I found
that astrocytic primary cilia became indistinguishable near injured tissue, while Arl13B
expression increased dramatically (Figure 13). We interpreted this result as likely
resorption of cilia allowing for proliferation or morphological alterations accompanying
astrocytic reactivity. To support our conclusion of ciliary ablation, we used IFT88, an
additional ciliary antibody, known for staining a protein involved with ciliary trafficking, to
determine presence of astrocytic cilia, but the stain proved unsuccessful. Due to the
absence of an additional astrocytic cilia marker proven to be effective in vivo, we cannot
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conclusively state that astrocytic primary cilia are fully eliminated near injured tissue, but
the absence of primary cilia would effectively indicate the proliferation of astrocytes
needed in formation of a glial scar around the injured cortex.
The translocation of Arl13B away from primary cilia and upregulation near the
injured cortex was unexpected but uncovered a potentially important role for this
GTPase in brain injury. To ensure that the upregulation of Arl13B was not due to nonspecific binding of the antibody, we used immunohistochemistry of Arl mice, void of the
requirement of antibody staining of Arl13B. Injured specimens displayed the same
increase in Arl13B expression, thereby removing the possibility of the intensity being the
result of an antibody issue and confirming the Arl13B is in fact upregulated in traumatic
brain injury induced astrocytic reactivity.
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CHAPTER 4

ARL13B IN BRAIN INJURY

i.

ELEVATED EXPRESSION NEAR CORTICAL LESION

The increase of Arl13B expression proximal to the injury site in our original
studies was ultimately surprising. We hypothesized that astrocytic cilia would be
reduced or ablated due to the requirement of ciliary resorption prior to mitosis [9].
Arl13B presence in primary cilia was drastically limited (Figure 13) but we cannot
definitively state that astrocytic cilia were completely removed due to the absence of an
additional and effective antibody.
Using our initial results as a foundation, I postulated that Arl13B upregulation
would align with the heightened expression of GFAP, a hallmark of astrogliosis. We
assumed that Arl13B would translocate into the cell body, allowing for alterations in
cellular function and/or signaling. I continued to use immunohistochemistry and ImageJ
analysis to identify Arl13B and GFAP intensity in brains which underwent a cortical stab
wound injury.
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Figure 13: Cortical Injury Promotes Arl13B Expression. Figure sourced from Sterpka et al., 2020 [6].
Absence of Arl13b-positive astrocytic primary cilia but robust Arl13b expression in tissues proximal to
injured sites. a-b Increased Arl13b expression proximal to an injury site (b) compared to a non-injury site
(A). Scale: 5 μm. Note that Arl13b-positive primary cilia were detected in non-injured tissues (a), but
undetectable in injured tissues (b). c the percentage of ciliated cells near injury sites decreased
dramatically compared to control tissues (left). ***, p < 0.001, unpaired student’s t-test. Injured tissues:
total cell number: 665, ciliated cell N: 13; non-injured tissues: total cell number: 265, ciliated cell number:
47. Injured tissues had significantly increased percentage of Arl13b-positive cells compared to that of
non-injury tissues (right). ***, p < 0.001, unpaired Student’s t-test, N = 3. Injury site cell N = 806; non-injury
site cell number 600. Two Arl13b images from injured and non-injured sites are shown in the left. Noninjury sites were from the opposite hemisphere of the injury site of same mouse. d Increased Arl13b
expression near injured sites in the cortex of C57BL/6 mice. GFAP (cyan) and Arl13b (red) were stained
with their antibodies, respectively. Left, non-injured site; right, injured site. e Increased Arl13b expression
near injured sites in Arl mice. Red: Arl13b-mCherry; Cyan: immunofluorescence staining using anti-GFAP
antibody. f Distinct Arl13b expression density in injured and non-injured tissues. Arl13b had the highest
expression near to the injury site. N = 5. g GFAP expression was strongly increased near to injured
tissues compared to non-injured tissues. h Correlation of relative expression density of GFAP and Arl13b
over a range of 500 μm distance from the injured site. ***, p < 0.001 by correlation analysis

Approximately two weeks after cortical injury, the heightened amplitude of Arl13B
aligned with the increase of GFAP expression characteristic of astrocyte reactivity
(Figure 13). The increase in intensity of Arl13B indicates that this accepted ciliary
protein must translocate out of the primary cilium into the soma or processes in order to
reach full functional potential. Its GEF activity of Arl3 and role in trafficking of INPP5E
indicate that this shift may be required for proliferation [103, 165]. Furthermore, it is
possible that Arl13B, in being a unique GTPase, may have other unknown roles,
particularly in the case of brain injury and the reparations that follow. The increase of
Arl13B appeared around cell bodies and aligned with the heightened expression of
GFAP, thereby aligning with reactivity and suggesting a previously undefined role.

ii.

STRAIN-DEPENDENT FUNCTION OF ARL13B IN BRAIN INJURY

The atypical GTPase, Arl13B, is known to function in ciliary trafficking of vesicles
[131], GEF activation of ARL3 [102], and cancer cell migration [87]. Furthermore, Arl13B
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is known to function in the translocation of INPP5E, a ciliary protein known to function in
proliferation [103, 110], as well as modulate Shh components [49, 113, 166].
Our initial study built a foundation implicating the function of Arl13B in brain
injury. Its function in trafficking signaling proteins, role in proliferative elements,
migratory capacity, and transduction of Shh all support its relevance in astrocytic
reparatory functioning. We accordingly hypothesized that Arl13B would work to support
astrocytic reactivity and impact glial scarring. To explore this, I used strains of mice to
act as a loss-of-function, control, and gain-of-function of Arl13B. These strains included
Arl13Bflox/flox; UBC treated with tamoxifen to ablate Arl13B, Arl13B flox/flox; UBC treated
with a vehicle as a control, and Arl13B-mCherry; Centrin2-GFP showing an
overexpression of Arl13B.
Results:
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Figure 14: Effect of Arl13B Expression on GFAP Expression. Arl13B and GFAP immunostaining
results seven days following injury of wildtype (blue), Arl13B Gain-of-Function (red), Arl13B Loss-ofFunction (green), and Ift88-Knockout (black). All mice show a heightened intensity of Arl13B close to
lesion site (0 on x-axis) with a higher expression of Arl13B in control tissue. Heightened GFAP
expression, indicative of glial scarring and neural repair, is not consistently enhanced or decreased with
regard to Arl13B or ciliary expression in mice.

Seven days following cortical lesion, vehicle treated Arl13Bflox/flox; UBC mice
(control mice), Arl13Bflox/flox; UBC mice treated with tamoxifen (LOF mice), Arl13BmCherry; Centrin2-GFP mice (GOF), and IFT88flox/flox;UBC mice treated with tamoxifen
(KO) were sacrificed. All mice displayed a heightened expression of Arl13B in injured
tissue compared to control tissue distal from the injury site, consistent with previously
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published data [6] (Figure 14: A, C-F). This pattern of heightened Arl13B expression
suggests the continued involvement of this protein in brain injury across strains.
The increased display of Arl13B in the Arl13B floxed mice indicates that its
knockout may not be ubiquitous in this strain and that it maintains a role in the
reparations following brain injury, regardless of reductions in expression. The
heightened level of Arl13B in the injury tissue of IFT88 Knockout mice supports reports
that Arl13B does not require localization on the primary cilia in order to be functionally
relevant [97].
GFAP expression was heightened in the injury tissue of all four strains, indicative of
the development of reactive gliosis. GFAP expression did not show significant trends
between strains, although visibly lowest in the WT strain and highest in the Arl13Bfloxed
LOF mice (Figure 14B). With the high levels of GFAP expression also observable in the
results of cortical lesions in IFT88 KO and GOF mice (Figure 14B), there is no direct
evidence of effect of Arl13B expression with the development of GFAP-based glial
scarring at 7 days following cortical lesion.

iii.

SLEEP ANALYSIS OF ARL13B-MCHERRY; CENTRIN2-GFP MICE

To examine sleep patterns of Arl mice, Electroencephalogram/Electromyogram
(EEG/EMG) recordings were used to score cortical and muscular activity patterns into
Wake, NREM, and REM. Wake activity represents cognitive alertness and muscular
activity of most mammals [167]. Sleep can be divided into Non-Rapid-Eye-Movement
(NREM) and Rapid-Eye-Movement (REM) activity [168, 169]. NREM comprises the
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majority of sleep activity, it can be split into three stages and is characterized by high
Delta activity [170]. REM sleep exhibits an extremely high amplitude and can occur in
microbursts or in slightly longer periods during NREM [40]. It is characterized by brain
activity similar to the waves seen during wakefulness, along with reduced EMG activity
and quick eye movements [171]. REM sleep is accompanied by high Theta activity
[172]. Examination of these EEG/EMG patterns can yield trends and disruptions in
activity based on genotype and phenotype.
Wake

NREM

REM

80 uV
2 sec

Figure 15: Sleep Stages of Arl Mice. EEG/EMG activity was staged into Wake, NREM, and REM in Arl
mice. Wake displayed high EMG activity, while both NREM and REM showed far less EMG activity. EEG
recordings showed a high power in NREM, but a lower power and higher frequency in REM activity. EEG
activity shown in upper row, EMG activity shown on lower row.

In four mice used for seizure verification, the first twenty-four hours was scored
with Sirenia Sleep Pro scoring software (v. 2.1.0). To maintain consistency with
analytics from Sirenia, power was set to Sleep Pro defaults as listed in Methods. Activity
was first scored into Wake and NREM via cluster scoring of EEG2 Delta against EMG
50-150. Activity was then visually confirmed and scored by the following criteria: Wake
was associated with moderate to high EMG activity; NREM maintained low EMG activity
and high EEG power; REM displayed low EMG activity, but low power and high
frequency (Figure 15).
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Results
Analysis of seizure activity in Arl mice showed
the occasional presence of artifacts and possible
seizures in mice phenotyped as controls. Thus,
equal sexes of two “control” and two “seizure” mice
were pooled together for this analysis to account for
the abnormal cortical activity present in this strain
and inability to fully account for a singular or rare
seizure occurrence. This combination supports a
more accurate analysis of the Arl strain.
Arl mice displayed increased wake activity
during night, and increased NREM during the day
(Figure 16). REM activity was observed to be
highest just prior to the onset of lights out (Figure
16). The first twenty-four hours following recording
revealed 53.26% of averaged wake time, 40.39%
NREM, and 3.40% REM. Sleep was separated into
92.25% NREM activity and 7.75% REM (Figure 17).
Wake and NREM durations are comparable to those
reported in other experiments, although REM activity

Figure
16:
Sleep
Score
throughout Day. Arl mice exhibited
higher levels of wake activity in the
absence of light and higher levels or
NREM and REM during the
presence of light. REM activity
spikes prior to the removal of lights.
X-axis shows four-hour increments
of time.

in Arl mice quantified in this study is less than that of percentile reports of other strains
[118, 173].
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Figure 17: Sleep Analysis Arl Mice. Arl mice revealed just over half of the first day of EEG/EMG
recording in wake, with the remaining time primarily spent in NREM. Only 3.39% of this 24-hour recording
was spent in REM activity. Analysis of time spent asleep revealed that REM activity comprised 7.75% of
the duration of sleep, with the remaining time spent in NREM.

Percentages of REM activity reported of old and young C57BL/6 recorded over
twenty-four hours mice and interpreted by Wimmer et al. [173] are both higher than that
of the Arl mice examined in this data collection. Additionally, REM activity of AC3 +/+
mice reported in a sleep analysis examining the role of AC3 in Major Depressive
Disorder by Chen et al. [118] is comparable, although higher than that of the Arl mice
examined in this experiment. This reduction of REM activity in Arl mice could be a result
of the disruption of normal environment by connection to Pinnacle recording software
and immediate recording, or due to the spontaneous seizure activity reported in this
strain.
Seizure occurrence is distinctly reduced during REM stages [174] and is reported
to have an inverse correlation with the length of REM activity during sleep [174]. It has
been reported that epilepsy and seizure activity reduce REM duration [175, 176], and
approximately only 1% seizures occur during REM sleep [175]. Theta activity,
associated with REM sleep, is reported to have an overall inhibitory effect on seizure
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activity [177]. Increased seizure activity has been correlated with deficiencies in REM
stages in cats [178], although there are limitations in scientific investigations to the
direct effect of seizure activity on REM sleep in mice. Thus, it is likely that the reduced
REM activity extracted from the EEG/EMG recordings of these Arl mice (Figure 17) is a
result of epileptic behavior and the presence of seizures in this strain.
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CHAPTER 5
EEG WAVEFORM ANALYSIS OF MOUSE MODEL OF ALZHEIMER’S DISEASE
UNDER ISOFLURANE-INDUCED ANESTHESIA
The following experiments sought out to determine if EEG waveform analysis of
a mouse model of AD contains hallmarks unique to the disease prior to manifestation of
cognitive defects. Burst Suppression Density (BSD), Power Spectral Density (PSD), and
Phase Amplitude (PAC) were investigated in EEG2 recordings of subjects exposed to
15 minutes of isoflurane anesthesia. This sedation was intended to reduce the noise
from peripheral neuronal firing seen during wake, thereby allowing for a controlled and
uninterrupted waveform, reminiscent of sleep and repeatable in all subjects.

i.

BURST SUPPRESSION OF APP23 MICE

APP23 mice are transgenically engineered to display the Alzheimer’s phenotype
starting at approximately 3 months of age [150]. This strain carries a double mutation
[human] expressed in the neocortex and hippocampus [150] and is specific for neuronal
expression [179]. This mutation is enacted by the Thy1 promotor [179], and this strain
exhibits amyloid-beta and tau levels in its cerebrospinal fluid indicative of the
development of AD starting as a mature adult [150]. The phenotypic changes that
progressively worsen with age include deficiencies in completing the Water Morris maze
[180], inadequacies in contextual fear conditioning [181], and disturbances in sleep
[182].
Isoflurane anesthesia is reported to be associated with BSD [145, 183]. Burst
suppression is a pattern of EEG activity that shows suppressed activity of neurons
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indicated by a flat (isoelectric) or near-flat EEG followed by short bursts of high activity
[145]. This is commonly associated with anoxia, hypothermia, coma, and other
pathologies that implicate the brain [145]. This electrical behavior is caused by the
depletion of intracellular calcium inhibiting synaptic signaling, thereby causing the
reduced activity [184]. This is followed by neuronal pumps restoring calcium and
allowing for heightened neuronal signaling in the form of a burst [145, 184]. The natural
(without intervention) incidence of burst suppression is associated with a poor
prognosis, with longer periods of isoelectric activity being insidious [145, 184].
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Figure 18: Burst Suppression Density of APP23 Mice. A. EEG2 recordings of 3–4-month-old Control
(left) and APP23 mice (right) show visual differences in patterning minutes 5-6 and 10-11 of isoflurane
exposure. X Scale: 50uV; Y Scale 5 seconds. B. 3–4-month-old age range show a significantly (p,0.05)
higher density of suppressed epochs than Control mice of the same age range. C-E. Changes of BSD
shown over the 15 minutes of isoflurane exposure. Control: blue; APP23: red) Significance calculated
with the Mann-Whitney test.

Isoflurane exposure is reported to elicit Burst Suppression patterning [145]. Thus,
our findings of this activity in anesthetized mice were not unexpected. We explored
young (3-4 months), middle-aged (5-7 months) and old (8-10 months) mice and found
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that all ages showed an increase in BSD from the beginning until end of 15 minutes of
isoflurane exposure (Figure 18 C-E). The percentage of suppressed epochs increases
with the length of isoflurane exposure in all age groups but remains higher in 3-4- and 57-month-old APP23 mice (Figure 18 C-D). The percentage of suppressed epochs
increases with the length of isoflurane exposure but shows mixed density between 8-10month-old APP23 mice and Controls.
Note the high levels of electrical activity on the left side of the panel of both
Controls and the near Isoelectric activity on the two mice on the right panel (Figure 18
A). I found that the youngest age group showed statistical relevance. These findings
show that while under isoflurane exposure, 3–4-month-old APP23 mice exhibit a
statistically significant difference in level of BSD than controls of the same age group
(Figure 18 B). No statistically significant differences were found in BSD of 5-7- and 810-month-old APP23 and Controls.
The absence of statistical difference of the older age groups is not completely
surprising, as the aged brain can exhibit various forms of compromise. This includes
affected BSD [185]. Our findings that BSD is statistically different in young mice is
promising in identifying a characteristic unique for the age group at the onset or prior to
the manifestation of the phenotype, thus supporting our hypothesis and development of
the foundation of a new method of AD evaluation.
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ii.

POWER SPECTRAL DENSITY ANALYSIS OF APP23
ELECTROENCEPAHLOGRAM

PSD is a common and well-established analytical method used to compare EEG
activity [132, 186, 187]. It analyzes the distribution of EEG waveform power, composing
oscillations into quantifiable frequency bins [132]. The respective frequency reflects
cortical cell activity with respect to amplitude and the average power over time. Each
frequency, or brain wave, is associated with a degree of consciousness [188].
The frequencies evaluated with PSD include Gamma, Beta, Alpha, Delta, and
Theta [188]. They are associated with the following types of consciousness and brain
activity: Gamma is associated with intra-brain communication, voluntary movement,
learning, and memory processing [188, 189]; Beta is dominant during periods of wake
and characteristic of an actively engaged mind [188, 190]; Alpha relates to a drowsy
and relaxed state [188, 190]; Theta occurs normally with REM sleep and dreaming [172,
188, 190]; and Delta brain waves are seen in slow wave sleep and NREM sleep [188,
190]. As isoflurane sedation was used to mimic sleep-like behavior in oscillations of the
brain, the following experimental design targets data collected from Alpha, Theta, and
Delta.
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Figure 19: EEG Comparison of APP23 Mice. Raw EEG recordings of APP23 mice display visibly
different characteristics. Figure shows 1-minute intervals of EEG2 extracted from 3-4-month-old mice (AB), 5-7-month-old mice (C-D), and 8-10-month-old mice (E-F). Recordings shown start 10 minutes
following the initiation of isoflurane exposure. Control mice shown on left and APP23 mice shown on right.
EEG scale 100 µV.

Raw samples of EEG2 recordings of the tenth minute of isoflurane exposure
display visible differences in 3-4-month-old Control and APP23 mice (Figure 19 A-B)
and 8-10-month-old (Figure 19 E-F). Minimal differences are observable in 5-7-monthold mice (Figure 19 C-D).
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Figure 20: Power Spectral Density of APP23 Mice. Brainstorm was used to derive Welch’s Power
Spectral Density per minute of isoflurane exposure into frequency bins. A-C: 3-4-month-old mice; D-F: 57-month-old mice; G-I: 8-10-month-old mice. A-C. Delta: blue; Theta: red; Alpha: green. Control: solid
line; APP23: dashed line.

At 3-4 months of age, relative frequency of Delta was lower in APP23 mice
compared to controls during Isoflurane exposure (Figure 20 A). Theta and Alpha were
higher in APP23 mice than in controls in this age range (Figure 20 B-C). Fluctuations in
power frequency bands were found in both 5-7- and 8-10-month age groups throughout
the duration of isoflurane exposure (Figure 20 D-I). This variation was especially
notable in the eldest age range (Figure 20 G-I).
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Figure 21: Average Power Spectral Density of APP23 Mice. Average relative frequency of different
powers was compared for its average over the duration of isoflurane administration. Brainstorm was used
to derive Welch’s Power Spectral Density per minute of isoflurane exposure into frequency bins and these
numbers were averaged over the total 15 minutes. A-C: 3-4-month-old mice; D-F: 5-7-month-old mice; GI: 8-10-month-old mice. A-C. Control: blue; APP23 red. Significance was calculated using the MannWhitney test.

At 3-4 months of age, the average of Delta was significantly (p < 0.0001) lower in
APP23 mice (Figure 21 A) while the averages of Theta and Alpha were significantly
higher (p < 0.0001) in APP23 mice (Figure 21 B-C). At 5-7 months of age, there was a
significantly higher average of Delta (p<0.05) (Figure 21 D); significantly lower average
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of Theta p<0.01) (E); and no significant difference in Alpha (Figure 21 F). At 8-10
months, APP23 mice showed a significantly (p<0.05) lower average of Theta (Figure 21
H), but no significance in the other frequencies shown.
The highest degree of statistical significance was found in the 3-4-month age
range (Figure 21 A-C), further supporting the visual difference seen in Figure 20.
Statistical significance was also found in 5-7-month-old mice in Delta and Theta and 810-month-old mice in Theta (Figure 21 D, E, H). The variations based on age, similarly
to the results of BSD can possibly be attributed to the aging brain, but the distinction in
young mice is highly relevant to the potential for early evaluation of AD prior to the onset
of symptoms.
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Figure 22: Comparison of PSD Between Young and Old APP23 Mice. Average PSD over isoflurane
administration was compared between groups of mice. A. 3-4-month-old Controls (blue) compared to 810-month-old Controls (yellow). B. 3-4-month-old APP23 (red) compared to 8-10-month-old APP23
(green). Statistical difference calculated with the Mann-Whitney test.

Comparison of average PSD during isoflurane exposure between young and old
mice showed statistically significant differences in frequencies examined. 8-10-monthold Control mice have significantly lower Delta (p<0.01), higher Theta (p<0.01), and
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higher Alpha (p<0.01) than 3-4-month-old Controls (Figure 22 A). 8-10-month-old
APP23 mice showed significantly higher Delta (p<0.0001), lower Theta (p<0.001), and
lower Alpha (p<0.001) than 3-4-month-old APP23 mice (Figure 22 B).

iii.

PHASE AMPLITUDE COUPLING OF APP23 MICE

Phase Amplitude Coupling (PAC) is a type of cross frequency analysis founded
on the patterning of high frequency bands nested within low frequency bands. PAC
shows fast oscillations propelled by slow oscillations, thereby being a measure of the
cohesion across different bands. This behavior indicates synchrony in populations of
firing neurons and consequently underlying mechanisms of neurological functioning
[191].
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Figure 23: Phase Amplitude Coupling of APP23 Mice. Maximum PAC was processed via Brainstorm
and analyzed between age groups. A: 3-4-month-old; B: 5-7-month-old; C.8-10-month-old. Control (blue);
APP23 (red). Samples of PAC extracted from Brainstorm are shown on right panel, correspondent with
the relevant age (D-F). Control – left; APP23– right. Significance calculated with the Mann-Whitney test.

Evaluation and comparison of maximum phase amplitude coupling of high
frequency gamma against low frequency Theta as derived from the MATLAB GUI
Brainstorm of young, mid-aged, and older mice did not elicit statistically significant
results (Figure 23). It is possible that the commonly used nested and nesting
frequencies (Gamma and Theta) were not relevant during anesthesia conditions. It has
been reported the PAC of Gamma and Alpha disrupt PAC [192]. Furthermore, it is
possible that the isoflurane sedation altered the presence of statistically significant
Gamma and Theta PAC detectable in EEG2 of APP23 mutants and Controls.
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CHAPTER 6

DISCUSSION & CONCLUSIONS
These studies aimed to elucidate the functionality of primary cilia and Arl13B in
the reactive mouse brain, as well as evaluate EEG waveform of a mouse model of
Alzheimer’s Disease. The subsequent sections discuss the conclusions of each project.

Part 1: CILIA LENGTH VARIANCE

This study began with exploring morphological differences between primary
cilium types, regions, and strains of mice. We hypothesized that primary cilia
morphology would be impacted by cell type and disease-like conditions. Investigations
moved forward to use epilepsy and cortical injury to produce different forms of reactivity
induction to trigger astrocytic change and determine what morphological changes occur
in primary cilia under reactive conditions.
Immunohistochemistry was first used as the primary tool to determine
morphological differences between astrocytic and neuronal primary cilia, as well as
regional differences in cilia type and strain of mouse. Results from these investigations
support evidence from other studies that neuronal cilia are significantly longer than
astrocytic cilia. This variation is likely attributed to the non-mitotic nature of neurons and
the maintained proliferative capacity of astrocytes. Astrocytes need for more dynamic
plasticity in primary cilia to support mitosis and are thus likely to exhibit shorter cilia.
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These studies went further to demonstrate that both neuronal and astrocytic
primary cilia display variations in length based on hippocampal region, and this variation
is partly dependent on murine strain. Neurons showed regional variance in all regions of
the hippocampus, while astrocytes displayed a marked shortening only in the dentate
gyrus of Arl13B-mCherry; Centrin2-GFP mice. It is possible that the regional variation of
neurons is due to region-specific function, although the difference in astrocytic cilia
length only in one strain of mice is unique and unexpected. It is possible that the
overexpression of Arl13B shown in this transgenic strain influences the cellular function
and likewise the ciliary function of astrocytes in this region. Staining and imaging
showed that differences in cilia length exist between strains. Staining was used to
further support the unreported elongation of both neuronal and astrocytic primary cilia in
the transgenic strain of Arl13B-mCherry; Centrin2-GFP mice, thereby identifying the
potential for this strain to bias results of morphological studies.
The structural dynamics of astrocytic and neuronal primary cilia were shown to
be influenced by spontaneously occurring seizures. This study is the first to verify a
morphological change is astrocytic cilia based on spontaneous seizure occurrence. It
further is the first to report that spontaneous audiogenic seizures reduce neuronal cilia
length as well. The systemic reactivity throughout the brain influenced by repetitive
seizure activity is also reported to propagate epileptic behavior. The heightened effect
on astrocytic cilia may be a result of the influence of long-term seizure activity or an
effector of the activity itself.
The first project in this thesis underscores the dichotomy between neuronal and
astrocytic cilia, with respect to brain region, strain of mouse, and pathogenic condition.
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These published results substantiate the hypothesis that primary cilia vary in
morphology based on cell-type and the presence and/or type of disease. They
additionally show that genotype can influence ciliary length. These findings illustrate the
significance of primary cilia in disease, thereby supporting their potential as a
therapeutic target.

Part 2: ARL13B IN BRAIN INJURY

The second project in this dissertation research sought out to evaluate the
presence of a role of the Ras GTPase Arl13B in reactive gliosis and the formation of
glial scarring, as indicated by altered GFAP expression. The project was founded on
findings from data collected from the first study, indicating that Arl13B expression is
enhanced near cortical injury following the reduction of Arl13B-positive primary cilia.
From these results, I developed the hypothesis that Arl13B overexpression or reduced
expression could be used to manipulate the degree of astrocyte reactivity.
Cortical injury resulted in undetectable Arl13B-primary cilia proximal to the injury
site and a marked decrease of neuronal ciliary length. IFT88, an additional ciliary
marker, was also unable to identify astrocytic cilia in these regions. Absence of
astrocytic primary cilia supports the hypothesis that astrocytes in the vicinity of
damaged tissue must proliferate, and consequently resorb their primary cilia, in order to
mitose and form a glial scar. The reduction in neuronal cilia length suggests signaling
differences potentially related to reparatory functions.
Immunohistochemistry was then analyzed for differences in protein expression
proximal to and distal to cortical location (ipsilateral and contralateral hemisphere,
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respectively) and genotype. Loss-of-Function, Gain-of-Function, Ciliary Knockout, and
Controls were compared at seven days post injury for Arl13B and GFAP. Our
hypothesis that Arl13B influences astrocyte reactivity in the form of altered GFAP
expression at seven days post injury was not substantiated by results from this study.
It is possible that a longer period of time from lesion induction may have
produced a difference in GFAP expression based on genotype, but seven days post
injury was selected due to reports of heightened GFAP expression at this time and the
ease in visualization of the injured cortex. Future studies may warrant focus on mice
fourteen days following lesion to determine potential links between Arl13B and GFAP.
These studies did not substantiate the role of Arl13B in neurological repair and
gliosis. Arl13B, a unique member of the Arl family, is still functionally unclear.
Immunostaining results showed that Arl13B protein expression is heightened proximal
to the injury site in all strains of mice used in this experimental design, but ablation and
overexpression of Arl13B did not enhance or reduce glial scarring at seven days
following cortical lesion.
This second research project did not support our hypothesis and did not establish
the relevance of protein Arl13B in reactive gliosis and neurological homeostasis. Ergo,
these findings do not provide evidence of Arl13B as a therapeutic target in gliosis-based
brain injury reparations of Arl13B GOF, Arl13B LOF, IFT88-based ciliary KO, or
C57BL/6BControl mice,
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PART 3: EEG WAVEFORM ANALYSIS OF A MOUSE MODEL OF AD

The aim of the third project in this dissertation research was designed to expand
the investigation of the pathogenic brain. This project was constructed to evaluate if
EEG recordings can be used to identify hallmarks indicative of the presence of the AD
prior to the onset of the AD phenotype. We hypothesized that while in a sedated state,
the uninterrupted waveform would yield characteristics that could contribute to early
diagnosis of AD.
APP23 mice, a mouse model of AD, were exposed to isoflurane anesthesia to
reduce the noise of neuronal firing seen in the roused and even sleeping brain. The
graphical user interface Brainstorm, a MATLAB-based platform, was used to filter
waveforms of young, middle-aged, and old mice and process for differences in power
spectral density, burst suppression density, and phase amplitude coupling.
During isoflurane administration, 3-4-month-old APP23 mice displayed a
significantly higher level of Burst Suppression Density than Controls in the same age
range. This age group also displayed significantly lower Delta Power Spectral Density
and higher Theta and Alpha averages. There was limited statistical difference found in
5-7- and 8-10-month-old mice, likely attributed to normal cognitive changes that can
occur with senescent change.
This third research project supported our hypothesis that while under anesthesia,
APP23 mice would show significant differences in EEG waveform as substantiated with
Burst Suppression Density quantification. Additionally, Power Spectral Density analysis
of this age group yielded statistically significant differences in Delta, Theta, and Alpha
frequencies, the powers relevant to relaxation and sleep.
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The findings of this third project are relevant in the development of clinical
evaluation of AD. EEG recordings during short procedures requiring anesthesia could
be introduced to evaluate risk of this disease and therefore offer the potential for early
intervention. These results are important in scientific understanding and implications of
Alzheimer’s.
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CHAPTER 7:

CONSIDERATIONS OF FUTURE WORK

This dissertation research focused on enhancing our understanding of the
pathogenic brain. Although the experiments yielded findings that elucidate the
involvement of primary cilia epilepsy and brains injury, the relevance of Arl13B in
cortical injury, and the identification of unique characteristics of EEG activity in early
Alzheimer’s, further work is needed to augment the importance and our understanding
of these results.
For the evaluation of ciliary variance, it would be appropriate to investigate the
difference in astrocyte and neuronal primary cilia in additional strains. The results
included in this dissertation explore neuronal and astrocytic primary cilia of Arl13BmCherry; Centrin2-GFP mice and two controls from their genetic background. A
comparison of strains that do not share the same degree of genetics would aid in a
better understanding of the strain-based variations that exist in mice.
Secondly, our findings of the previously described experiments consistently
showed Arl13B as intensifying in the region of cortical injury. Investigation of its
expression seven days following the lesion of cortical tissue of mice with an
overexpression or ablation of Arl13B did not show an upregulation or down-regulation of
GFAP expression. These findings do not support the hypothesis that Arl13B affects
GFAP-based reactive gliosis. Investigation of expression by a different means of
evaluation, such as qPCR could be relevant, but ineffective primers were a limiting
factor during the time of this study. It is also possible that Arl13B may play a role in a
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different feature of gliosis, such as the fibrotic tissue matrix that develops. Targeting this
tissue and examining a correlation with Arl13B may be a promising pursuit.
Finally, the investigations of AD discussed in this dissertation are the foundation
of a potentially important and large research project. In APP23 mice, the EEG waveform
could also be investigated for differences in the cortical region. Due to the strength of
signal, only EEG2 (prefrontal cortex) was used for analysis. EEG1, which transduces
activity from the occipital lobe, was not included. Furthermore, investigation of human
cortical activity would be very interesting and would require the collaboration of medical
doctors and continued participation of patients over time to identify cognitive changes.
The possibilities of investigating AD are highly extensive, and it is my hope that the
methods and results shown here provide a research foundation on which development
of early diagnostic tools for AD can be built.
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APPENDIX
i.

SUPPORTING TABLES
a. Table 3: Primary Antibodies used in Immunohistochemistry

Primary
Antibody
Arl13B

Species

Dilution

Catalog #

Binding

Mouse

1:250

Neuromab, 75–287

GFAP

Rabbit

1:750

Dako, 2024-05-31

AC3

Rabbit

1:10,000

IBA1
Ki67

Goat
Mouse

1:250
1:150

EnCorBiotechnology,
AB2572219
Abcam, ab5076
BD Biosciences,
550609

Astrocytic primary
cilia
Astrocytes,
Reactivity
measurement
Neuronal primary
cilia
Microglia
Proliferation marker
(any stage of
mitosis)

b. Table 4: Modified Racine Scale
Score

Behavior

0

No difference in behavior

1

Repetitive jaw twitch/chewing

2

Cranial bobbing and repetitive nodding

3

Involuntary movements accompanied with tremors

4

Involuntary movements accompanied by falling

5

Loss of muscle tone followed by death
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ii.

APPROVED IACUC PROTOCOLS
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